 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 1 of 59 
A PROSPECTIVE, MULTI- CENTER, RANDOMIZED, PARALLEL- GROUP STUDY COMPARING AMNIOEXCEL® 
PLUS  PLACENTAL ALLOGRAFT MEMBRANE TO APLIGRAF®  BI-LAYERED SKIN SUBSTITUTE AND 
STANDARD OF CARE PROCEDURES IN THE MANAGEMENT OF DIABETIC FOOT ULCERS  
 
 
SHORT TITLE: AMNIOEXCEL® Plus  vs Apligraf® vs SOC in the 
Management of Diabetic Foot Ulcers  
Protocol Number: T- AEPDFU -001 
Version Number:  3 .0 
Version Date: 05 Nov 2018 
 
Sponsor:  
Integra LifeSciences  
311 Enterprise Drive, Plainsboro, New Jersey 08536  
www.integralife.com   
Phone: +1 -609-275-0500 • Fax: +1 -609-750-4277 
Sponsor Contact (s):  
Main Contact:  
Jessica Knowlton, MS CRA  
Clinical Research Manager  
Phone: +1 -609-750-7825 • Cell: +1-609-325-0111  
 jessica.knowlton@integralife.com   
  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 2 of 59 
TABLE OF CONTENTS  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 5  
1 PROTOCOL SUMMARY  ............................................................................................................................... 6  
2 INTRODUCTION  .......................................................................................................................................... 14 
2.1 Study Rati onale  .................................................................................................................................. 14 
2.2 Background ......................................................................................................................................... 14 
2.3 Risk/Benefit Assessment  .................................................................................................................. 16 
2.3.1  Known Potential Risks  ................................................................................................... 16 
2.3.2  Known Potential Benefits  .............................................................................................. 19 
3 OBJECTIVES AND ENDPOINTS  .............................................................................................................. 20 
4 STUDY DESIGN  ........................................................................................................................................... 21 
4.1 Overall Design  .................................................................................................................................... 21 
4.2 Scientific Rationale for Study Design .............................................................................................. 21 
4.3 Justification for Investigational Products/Treatments  ................................................................... 21 
4.4 End of Study Definition  ..................................................................................................................... 21 
5 STUDY POPULATION  ................................................................................................................................ 22 
5.1 Inclusion Criteria  ................................................................................................................................ 22 
5.2 Exclusion Criteria  ............................................................................................................................... 22 
5.3 Lifestyle Considerations  .................................................................................................................... 24 
5.4 Screen Failures and Rescreening  ................................................................................................... 24 
5.5 Strategies for Recruitment and Retention  ...................................................................................... 26 
6 STUDY INTERVENTION ............................................................................................................................ 27 
6.1 Study Interventions Administration .................................................................................................. 27 
6.1.1  Study Intervention Descriptions  ................................................................................... 27 
6.1.2  Utilization and Administration  ....................................................................................... 28 
6.2 Handling/Storage  ............................................................................................................................... 31 
6.2.1  Acquisition and Accountability  ...................................................................................... 32 
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................................... 32 
6.4 Study Intervention Compliance ........................................................................................................ 32 
6.5 Concomitant Therapy  ........................................................................................................................ 33 
7 STUDY INTERVENTION DISCONTINUATION AND SUBJECT 
DISCONTINUATION/WITHDRAWAL  .................................................................................................................... 34 
7.1 Discontinuation of Study Intervention  ............................................................................................. 34 
7.2 Subject Discontinuation/Withdrawal from the Study  ..................................................................... 34 
7.3 Lost to Follow -Up ............................................................................................................................... 35 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 36 
8.1 Study Procedure Overview ............................................................................................................... 36 
8.1.1  Screening Visit 1 ( -2 Weeks [14 days] ± 3 days) ....................................................... 36 
8.1.2  Screening Visit 2 ( -1 Weeks [7 days] ± 3 days)  ......................................................... 36 
8.1.3  Randomization visit (day 0) – Point of Enrollment  .................................................... 36 
8.1.4  Week 1 (7 ± 3 days) through Week 11 (77 ± 3 days); Unscheduled Visits  ........... 37 
8.1.5  Week 12 (84 ± 3 days)  .................................................................................................. 37 
8.1.6  Follow -Up Visits - Weeks 13 & 14 (91 & 98 ± 3 days)  .............................................. 37 
8.2 Assessments  ...................................................................................................................................... 38 
8.3 Advers e Events and Serious Adverse Events  ............................................................................... 41 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 3 of 59 
8.3.1  Definition of Adverse Event (AE)  ................................................................................. 41 
8.3.2  Definition of Investigational Product  ............................................................................ 42 
8.3.3  Definition of Study Procedure ...................................................................................... 42 
8.3.4  Definition of Adverse Reaction  ..................................................................................... 42 
8.3.5  Definition of Serious Adverse Event (SAE)  ................................................................ 42 
8.3.6  Classification of an Adverse Event  .............................................................................. 43 
8.3.7  Time Period and Frequency for Event Assessment and Follow -Up ....................... 45 
8.3.8  Adverse Event Reporting  .............................................................................................. 46 
8.3.9  Serious Adverse Event Reporting  ............................................................................... 46 
8.3.10  Unanticipated Serious Adverse Event Reporting  ...................................................... 46 
9 STATISTICAL CONSIDERATIONS .......................................................................................................... 46 
9.1 Statistical Endpoints  .......................................................................................................................... 46 
9.2 Sample Size Determination  .............................................................................................................. 47 
9.3 Populations for Analyses  .................................................................................................................. 47 
9.4 Statistical Analyses ............................................................................................................................ 48 
9.4.1  General Approach  .......................................................................................................... 48 
9.4.2  Subject Disposition  ........................................................................................................ 48 
9.4.3  Protocol Deviations  ........................................................................................................ 48 
9.4.4  Baseline Descriptive Statistics  ..................................................................................... 48 
9.4.5  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 49 
9.4.6  Analysis of the Secondary Endpoint(s)  ....................................................................... 49 
9.4.7  Safety Analyses  .............................................................................................................. 49 
9.4.8  Planned Interim Analyses  ............................................................................................. 50 
9.4.9  Sub-Group Analyses  ..................................................................................................... 50 
9.4.10  Tabulation of Individual Subject Data  ......................................................................... 50 
9.4.11  Multiplicity Adjustment  ................................................................................................... 50 
9.4.12  Exploratory Analyses  ..................................................................................................... 50 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 51 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ........................................................... 51 
10.1.1  Informed Consent Process  ........................................................................................... 51 
10.1.2  Study Discontinuation and Closure  ............................................................................. 51 
10.1.3  Confidentiality and Privacy  ........................................................................................... 52 
10.1.4  Future Use of Data  ......................................................................................................... 52 
10.1.5  Safety Oversight  ............................................................................................................. 52 
10.1.6  Clinical Monitoring  .......................................................................................................... 53 
10.1.7  Quality Assurance and Quality Control  ....................................................................... 53 
10.1.8  Data Handling and Record Keeping  ............................................................................ 53 
10.1.9  Protocol Deviations  ........................................................................................................ 54 
10.1.10  Publication and Data Sharing Policy  ........................................................................... 55 
10.1.11  Conflict of Interest Policy  ..............................................................................................  55 
10.1.12  Financing and Insurance  ............................................................................................... 55 
10.2  Abbreviations and Definitions  .......................................................................................................... 56 
10.3  Protocol Amendment History  ........................................................................................................... 57 
11 REFERENCES  ............................................................................................................................................. 58 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 4 of 59 
FIGURES  
Figure 1: Study Schema  .......................................................................................................................... 12 
Figure 2: Screening Flow of Activities  ................................................................................................... 25 
Figure 3: Expectedness Determination of Investigational Product or Procedure- Related SAEs  45 
 
   
TABLES  
Table 1: Protocol Synopsis  ....................................................................................................................... 6  
Table 2: Schedule of Activities  ............................................................................................................... 13 
Table 3: Objectives and Endpoints  ........................................................................................................ 20 
Table 4: Abbreviations/Definitions  ......................................................................................................... 56 
Table 5: Protocol Amendment History  .................................................................................................. 57 
 
    
[Intentionally Blank]  
   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 5 of 59 
STATEMENT OF COMPLIA NCE  
 
By signing this document, I, the Investigator, certify that this trial will be carried out in accordance with 
International Conference on Harmonization  Good Clinical Practice ( ICH GCP) and the following :  
 
• United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 11, 21 CFR Part 50, and 21 CFR Part 56 ) 
 
Additionally, I and any  clinical trial site staff who are responsible for the conduct, management, or 
oversight of this trial will complete  Human Subjects Protection /ICH GCP Training. 
 
The protocol, informed consent form(s), any recruitment materials, and /or all subject  materials associated 
with this trial will be submitted to an Institutional Review Board ( IRB) for review and approval.  Approval 
of both the protocol and the consent form  must be obtained before any subject  is screened .   
 Finally, I understand that any amendment s to the protocol  or consent forms  will require review and 
approval by the Sponsor and IRB before the changes are implemented to the study.   
 
 
  
Investigator Name  
 
 
 
Investigator Signature  Date  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 6 of 59 
1 PROTOCOL SUMMARY  
 
Table 1: Protocol Synopsis  
Title:  A Prospective , Multi-Center , Randomized , Parallel -group  Study  Comparing  
AMNIOEXCEL P lus Placental A llograft  Membrane  to Apligraf Bi- layered Skin 
Substitute and Standard of Care  Procedures in the Management of Diabetic 
Foot Ulcers  
Short Title : AMNIOEXCEL Plus  vs Apligraf  vs Standard of Care ( SOC) in the Management of 
Diabetic Foot Ulcers  
Study Des cription : This is a multicenter, randomized, parallel -group study comparing the 
outcomes associated with the use of AMNIOEXCEL Plus  Placental Allograft  
Membrane, Apligraf bi-layered skin substitute and SOC  alone  in the 
management of diabetic foot ulcers  (DFUs) .  
Pre/Post -Market:  Post -Market  
Study Design:  This study will have three (3) phases: (1) a Screening Phase, (2) a Treatment 
Phase, and (3) a Follow -up Phase .  Subjects will be seen weekly in the Screening 
and Treatment Phases.  Subjects who achieve  wound closure during the 
Treatment Phase will be entered into the Follow -up Phase and will return to 
the site  for up  two (2) additional weeks for confirmation visit s.  A n interim 
analysis  will occur after 50% of subjects have reached the primary endpoint . 
Primary Objective:  The primary objective of this study is to compare outcomes associated with the 
use of AMNIOEXCEL Plus Placental Allograft Membrane, Apligraf living, bi -
layered skin substitute and SOC in the management of DFU s.   
Secondary Objective(s):  The secondary objectives of this study are to:  
1. Determine the proportion of subjects in each study arm with 
complete closure of the study ulcer at or before 12 weeks of 
treatment  
2. Determine the time to complete wound closure in each study arm  
3. Determine the rate of wound closure in each study arm  
4. Assess medical resource utilization outcomes in each study arm  
Safety Objective:  The safety objective of this study is to assess adverse events associated with 
any of the investigational products  and/or study procedures in the 
management of DFU s. 
Exploratory 
Objective(s):  The exploratory objectives of this study are to:  
1. Determine the proportion of subjects in each cohort whose wounds 
are closed at 4 weeks of treatment.  
2. Determine the effect of any covariate on the primary endpoint.  
Primary Endpoint : The primary endpoint of this study is the incidence of complete wound closure, 
as assessed by the Investigator at or before Week 12 of the Treatment Phase, which is c onfirmed closed two weeks later. C omplete wound closure is defined 
as complete skin re -
epithelialization that is without drainage or dressing 
requirements  
Secondary Endpoint(s):  1. The proportion of subjects in each group with complete closure of the study ulcer at or before Week 12 as assessed by computerized planimetry. 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 7 of 59 
2. The p roportion of subjects in each group with complete wound closure of 
the study ulcer at or before Week 12 as assessed by independent, blinded, 
assessm ent of photographs.  
3. The time to complete wound closure, as assessed by the Investigator.  
4. The time to complete wound closure  for all closed wounds in each group , 
as assessed by computerized planimetry.  
5. For those wounds that have closed, the  rate of wound cl osure  for each 
group , as assessed by computerized planimetry.  
6. Medical resource utilization associated with management of DFU and 
related complications as determined by a comparison of estimated costs from the presumed billing codes which would have been us ed for each 
patient.  
Safety Endpoint:  Incidence of all investigational product , procedure, and/or wound -related 
adverse events or serious adverse events.  
Exploratory 
Endpoint(s):  1. The p roportion of closed wounds in each group at Week 4 of the Treatment  
Phase   
2. Co-variate analyses of the primary endpoint using those listed in section 
9.3. 
Description of Study 
Intervention(s) : Intervention 1: SOC therapy consisting of the use of moist wound dressings , 
debridement, infection surveillance and management  and 
consistent and appropriate use of an offloading boot.  
Intervention 2: AMNIOEXCEL Plus  used in conjunction with SOC  therapy.   
Intervention 3: Apligraf  used in conjunction with SOC therapy.    
Indications for Use : AMNIOEXCEL Plus  is a human placental -based tissue consisting of dehydrated , 
tri-layer P lacental (Amnion/Chorion/Amnion) A llograft Membrane  (T-PAM)  
layers.  T- PAM is a minimally manipulated placental membrane product made 
from tissues donated by pre -screened mothers during planned C -sections and 
is intended for use as a wound covering. This product is an allograft tissue 
intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician.  AMNIOEXCEL Plus  contains Human 
Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271.  All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier au dits.  
 
Apligraf is a living, bi- layered skin substitute: the epidermal layer is formed by 
human keratinocytes and has a well- differentiated stratum corneum; the 
dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice.  It is indica ted for use with standard therapeutic compression for the 
treatment of non -infected partial and full- thickness skin ulcers due to venous 
insufficiency of greater than 1-month  duration and which have not adequately 
responded to conventional ulcer therapy.  Apligraf is also indicated for use with 
standard DFU  care for the treatment of full- thickness neuropathic DFU s of 
greater than three weeks’  duration which have not adequately responded to 
conventional ulcer therapy and which extend through the dermis but w ithout 
tendon, muscle, capsule or bone exposure.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 8 of 59 
Study Population:  114 subjects, at least  21 years of age  with a DFU  will be randomized into  this 
trial in the United States . 
Inclusion Criteria  All of the following criteria must be met  by a potential subject to be enrolled  
(i.e., randomized)  in the study.  The subject must:  
1. Have participated in the informed consent process and signed a study -
specific informed consent document.  
2. Be able and willing to comply with study procedures, including study visits, 
study dressing regimens, and compliance with study required offloading  
device . 
3. Be ≥ 21 years of age.  
4. Have Type I or Type II diabetes mellitus with Investigator -confirmed 
glycosylated hemoglobin (HbA1c) of ≤ 12% within 3 months prior to 
screening visit.  
5. Have at least one diabetic foot ulcer that meets ALL of the following criteria:  
• Ulcer has been in existence for a minimum of four weeks prior to signing the Informed Consent Form for trial participation but no more than 12 months  
• Ulcer is a partial or full thickness diabetic foot ulcer without 
capsule/tendon/bone exposure (Wagner Grade 1 or superficial 2).   
• Ulcer is located on the foot or ankle (with no portion above the top of the malleolus, i.e., proximal to the malleolus).   
• If the subject has more than one ulcer that meets the eligibility criteria, 
the ulcer designated as the study ulcer will be at the discretion of the Investigator.   
• There is a minimum 1 cm margin between the qualifying study ulcer and any other ulcer on that  same foot, post -debridement.  
6. Ulcer size (i.e., area) is > 1 cm
2 and < 12 cm2 post -debridement at Screening 
Visit 1 and Randomization (Day 0).  
7. Have adequate vascular perfusion of the affected limb as defined by at 
least one  of the following  (in order of pr eference) : 
• Ankle -Brachial Index (ABI) ≥ 0.65 and ≤1.2, performed within 3 months  
of screening visit 1  
• Toe pressure (plethysmography) >50 mmHg at time  of screening  visit 
1, 
• TcPO 2 >40 mmHg at time  of screening  visit 1  
8. Be willing and able (or have a family  member /friend willing and able) to 
apply required applicable dressing changes as well as study -required 
offloading /protective device if and when applicable.  
Exclusion Criteria  Potential subjects will not be enrolled in the study if any of the following criteria are met:  
1. The subject was previously randomized and treated under this clinical 
study protocol.   
2. The study ulcer has:  
a. Unexplored tunneling,  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 9 of 59 
b. Undermining and/or  
c. Sinus tracts  
that necessitates surgical operating -room debridement and/or penetrates 
to capsule/tendon/bone.  
3. The subject has a known sensitivity to ethanol.  
4. The subject has  a known allergy to bovine collagen.  
5. The subject has  a known hypersensitivity to any of the components of the 
Apligraf agarose shipping medium listed below:  
o agarose,  
o L-glutamine,  
o hydrocortisone,  
o human recombinant insulin,  
o ethanolamine,  
o O-phosphorylethanolamine,  
o adenine,  
o selenious acid,  
o DMEM powder,  
o HAM’s F- 12 powder,  
o sodium bicarbonate,  
o calcium chloride  
6. The subject has  a known sensitivity to any of the SOC  materials  which come 
in contact with the skin : 
o Coban™  
o Conforming gauze  
o Optifoam® non -adhesive dressing 
o Normal Saline (liquid or gel)  
o Cotton Gauze  
o Normal saline (liquid & gel)  
o Non -adhering dressings  
o Steristrip s 
7. The subject is unable to safely ambulate with the use of a study required 
offloading  boot . 
8. The subject has  suspected or confirmed gangrene or wound infection of 
the study ulcer, as evidenced by tissue necrosis, redness, pain, and/or 
purulent dr ainage and/or receiving systemic antibiotics for the treatment 
of such.  
9. The subject has  suspected or confirmed osteomyelitis of the foot with the 
study ulcer.   
10. The subject has  participated in another clinical trial involving a device or an 
investigational study drug/treatment within 28 days of randomization.  
11. In the opinion of the Investigator, the subject has received, within 28 days 
of signing the Informed Consent Form, or is scheduled to receive during 
study participation, a medication or treatment which is known to interfere 
with or affect the rate and quality of wound healing (e.g., systemic steroids, 
immunosuppressive therapy, autoimmune disease therapy, dialysis, 
radiation  therapy to the foot, vascular surgery, angioplasty, or 
thrombolysis).  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 10 of 59 
12. The subject has a history of bone cancer or metastatic disease of the 
affected limb, radiation therapy to the foot, or has had chemotherapy 
within the 12 months prior to signing the Inf ormed Consent Form for trial 
participation.  
13. The subject is currently pregnant or is actively trying to conceive.  ( Patient 
statement confirming lack of pregnancy is sufficient. ) 
14. In the opinion of the Investigator, the subject is unable to comply with the treatment regimen (i.e., return for clinic visits, perform required dressing 
changes and use study -designated offloading  device(s)).  
15. In the opinion of the Investigator, the subject has a history of, or is currently diagnosed with, any illness or condition,  other than diabetes, that could 
interfere with wound healing (e.g., end -
stage renal disease, severe 
malnutrition, liver disease, aplastic anemia, Raynaud’s Syndrome, 
connective tissue disorder, acquired immune deficiency syndrome, HIV 
positive, or sickle cell anemia).  
16. In the opinion of the Investigator, the subject has unstable Charcot foot or 
Charcot with bony prominence that could inhibit wound healing.  
17. The subject h as ulcers secondary to a disease other than diabetes (e.g., 
vasculitis, neoplasms, or hematological disorders).  
18. In the opinion of the Investigator, the subject has excessive lymphedema 
that could interfere with offloading  and/or wound healing.  
19. The study ulcer has received wound dressings that include growth factors, engineered tissues, or sk in substitutes within 28 days of randomization or 
is scheduled to receive treatment during the study  
(e.g., PriMatrix, 
AMNIOEXCEL  (first generation) , Regranex, Dermagraft, EpiFix, GraftJacket, 
OASIS, Omnigraft, or Integra BMWD).  
20. The study ulcer closed more  than 30% in area, post -debridement , between 
Screening Visit 1 and Randomization (Day 0, as measured by planimetry).  
Description of 
Sites /Facilities  
Enrolling Subject s: Up to 15  sites will participate in this study.  All sites will be located in the 
United States.   Each site may enroll up to 38 subjects.  
Study Duration:  This study is anticipated to have an enrollment period of  up to  2 years.  Total 
duration of the study is expected to be up to 2 years.  
Subject  Duration:  All subjects will have a SOC screening period of up to 2 weeks  ± 3 days  prior to 
randomization ( Day 0) .  Investigational product with SOC treatments  or SOC 
alone t reatments will begin  on Day 0 (randomization)  and will be applied 
weekly for up to 11 weeks  ± 3 days .  If the wound closes on or before week 11, 
follow -up will begin and will last 2 weeks ± 3 days  after the date of closure .  If 
the wound does not close by week 12, the subject will be immediately exited from the study and no further follow -up will occur as part of the st udy. The 
total duration for a single subject  may last up to 1 6 weeks  ± 3 days . 
Statistical Methods  & 
Analyses : This is a prospective, multicenter, parallel -group, randomized, three -arm trial 
designed to assess the proportion of subjects achieving complete wound 
closure of their DFU s, in a population with adequate arterial circulation, 
following up to 1 1 weeks of tr eatment receiving either AMNIOEXCEL Plus  
Placental Allograft Membrane with SOC , Apligraf bi-layered skin substitute with 
SOC, or SOC alone.  Subjects will be randomized 1:1:1, to receive either 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 11 of 59 
AMNIOEXCEL Plus  Placental Allograft Membrane with SOC, Apligra f bi-layered 
skin substitute with SOC , or SOC alone.  
 
Sample Size  
A total of 114 subjects , 38 per cohort,  will be randomized , inclusive of a 20% 
in-study attrition rate.    
 
It is assumed that the maximum wound closure rate is 90% with no difference 
between the study cohorts.  Based on the 38 subject per cohort sample size , 
the half width of the 95% confidence interval for the wound closure rate is 
13.5%.    However, the study is not adequate for hypothesis  testing.  
 
Data Evaluation 
The Intent- to-Treat (ITT) population, defined as all randomized subjects, will be 
the primary population for the analysis of primary and secondary efficacy 
endpoints.   
Analysis Population  
 The Per Protocol (PP) population, defined as all subjects who complete the study without a major protocol violation, will be used as the primary analysis dataset.  
 Primary Efficacy Analysis  
 For the primary efficacy analysis, ITT population will be used.  The proportion 
of subjects with complete wound closure, will be compared using the Cochran –
Mantel –Haenszel (CMH) test.   For the primary efficacy analysis, missing values 
will be imputed using last observation carried forward (LOCF).  The difference s 
in complete wound closure rate s between treatment arms will be summarized 
and 95% confidence intervals  calculated . 
 Safety Assessment  
 
Adverse Events related to the investigational products , study ulcer and/or 
study procedures and all Serious Adverse Events wi ll be recorded.  
All safety parameters will be summarized descriptively by treatment 
assignment.  No inferential statistics are planned.  
 Exploratory Analyses  
 
Exploratory analyses will be performed to examine wound closure status at 
Week 4 of Treatment  and co -variate impact on the primary endpoint.  
 
 Integra LifeSciences   
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 12 of 59 
Study Schema  
 
           
Eligibility  
49±3 days      Week 7  
42±3 days      Week 6  
35±3 days      Week 5  
28±3 days      Week 4  
21±3 days      Week 3  
14±3 days      Week 2  
7±3 days      Week 1  
77±3 days      Week 11  
70±3 days      Week 10  
63±3 days      Week 9  
56±3 days      Week 8  
84±3 days      Week 12  
91±3 days      Week 13  
98±3 days      Week 14  
Screening Visits  
 Follow -Up 
 
Apligraf® + Standard of Care 
  
AMNIOEXCEL® Plus + Standard of Care  
  
Standard of Care                     .  
•Patient Assessments  
•Photography  
•Debridement  
•Treatment (Weeks 1 through 11, as applicable) not last visit)  
•Offloading & Compliance  
•MRU (Except for Screening)  
•Concomitant Medications  
•Adverse Events   
• Only occurs if wound is closed.  
Second follow -up only occurs if 
wound remains closed on first follow -up. 
• Offloading Continues without dressings if Wound is closed . 
• MRU & Patient Assessments  
• Photography  
• Concomitant Medications  
• Adverse Events   
 
Randomization       Day 0  
-7±3 days       -1 Weeks  
-14±3 days       -2 Weeks  
•Informed Consent  
•Eligibility Criteria  
•Demographics & Med History  
•Physical Exam  
•Vascular Perfusion 
Assessment  
Figure 1: Study Schema  
 Integra LifeSciences   
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 13 of 59 
Table 2: Schedule of Activities  
 Screening  Treatment  Follow -Up Visits   
Procedure s  
 (See Section 8 for 
details)  Visit 1  
-2 Weeks  
-14±3 days  Visit 2  
-1 Week  
-7±3 days  Random -
ization  
Day 0  Week 1  
7±3 days  Week 2a 
14±3 day  Week 3a 
21±3 days  Week 4a 
28±3 days  Week 5a 
35±3 days  Week 6a 
42±3 days  Week 7a 
49±3 days  Week 8a 
56±3 days  Week 9a 
63±3 days  Week 10a 
70±3 days  Week 11a 
77±3 days  Week 12a 
84±3 days  Visit 1b 
Week 13  
91±3 days  Visit 2b 
Week 14  
98±3 days   Unsched. 
Visit  
Inf. Consent  & HIPAA  X                  
Eligibility Criteria  X Xc X                
Demographics & 
Medical History  X                  
Physical Examination  X                  
Vascular Perfusion 
Assessment  X                  
Treatment  Compliance 
Review  X X X X X X X X X X X X X X X   X 
Debridementd X X X X X X X X X X X X X X    X 
Photography  X X X Xe X X X X X X X X X X X X X X 
Ulcer Assessmentsf X X X X X X X X X X X X X X X X X X 
Standard of Careg X X  X X X X X X X X X X X     
Boot Applicationh X X X X X X X X X X X X X X X X X X 
Randomization    X                
Investigational Prod.i   X Xj X X X X X X X X X X    X 
MRU Assessment     X X X X X X X X X X X X X X X 
ConMeds & Procedures  X X X X X X X X X X X X X X X X X X 
Adverse Events   X X X X X X X X X X X X X X X X X 
                                                                 
 
a Optional Visit – Conducted if wound is not closed  
b Optional Visit – Complete ulcer  is closed by Week 1 2.  Follow -up visit 2 only occurs if 
wound remains closed on Follow- up visit 1.  Otherwise subject is exited.  
c Exclusion  based on Ulcer Area not applicable at this visit  
d If Investigator deems it necessary  
e If subject has been randomized to Apligraf, imaging may not occur at this timepoint.  See 
sections 8.1.2 or 8.2 for detailed instructions.  
f Study Ulcer Assessments at 1st visit include: 1) location and 2) duration.  At each 
subsequent visit, ulcer area, area reduction, level and type of exudate, presence of 
signs/symptoms of infection will be made  g Weekly and daily dressing changes during Sc reening; Daily continues only  if randomized to 
SOC cohort.  
h Offloading boot required for ulcers  on lateral or bottom part of the foot.  Boot may be 
used as a protective device for those subjects with ulcers on the dorsum of the foot  
i Investigational Product = AMNIOEXCEL Plus or Apligraf is added to SOC Treatment if 
applicable per randomization, see also footnote e . 
j If Apligraf being used, non -adherent dressing should be left in place on day 7.  See Section 
6.1 for more information.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number  3.0  Page 14 of 59 
2 INTRODUCTION  
 
2.1 STUDY RATIONALE   
 AMNIOEXCEL®  (Integra LifeSciences Corporation, Plainsboro, NJ ) is a commercially available dehydrated 
amniotic membrane allograft (DAMA) used in  advanced wound care. The product is provided in multiple 
geometric configurations to be applied directly to clean, debrided wounds where bacterial burden and offloading have been addressed.
1  Other advanced wound care therapies, including biological dressings 
such as Apligraf® (Organogenesis, Canton, MA, USA) and EpiFix® (MiMedx Group Inc., Marietta, GA) , have 
been used in various types of ulcers  including the treatment of DFU s.2,3 
 The composition of these advanced wound care allografts varies .  Whereas AMNIOEXCEL is a dehydrated 
amniotic membrane allograft, Apligraf is a living, bi- layered skin substitute: the epidermal layer is formed 
by human keratinocytes and has a well- differentiated stratum corneum; the dermal layer is composed of 
human fibroblasts in a bovine Type I collagen lattice.
4  Another allograft, EpiFix ®, is similar to AMNIOEXCEL , 
but includes the chorion layer in addition to the amnion layer [a dehydrated human amnion/chorion 
membrane(dHACM)] . 
 Recently, Integra LifeSciences has developed AMNIOEXCEL ® Plus Placental Allograft Membrane  
(AMNIOEXCEL Plus) which , unlike its predecessor , AMNIOEXCEL,  retains the chorion layer of tissue  and 
goes further to add another layer of amnion creating an amnion -chorion -amnion sandwich .  The study 
detailed in this protocol has been designed to assess the use of AMNIOEXCEL Plus  in the clinic against a 
comparator product (Apligraf) and SOC  procedures.  
 2.2 BACKGROUND   
 Diabetic foot ulcers (DFU s) are a major health complication that will affect up to 15% of individuals with 
diabetes mellitus over their lifetime.  The treatment of DFUs is an extremely challenging scenario, as these ulcers may be recalcitrant to SOC treatments , thus  increasing the risk of infection  and sequelae such as 
amput ations . It is estimated that approximately 15% of all DFUs will result in a lower extremity amputation 
and develop concomitant medical complications that are associated with increased mortality rates.
5–8 
 DFU s not only have a detrimental effect on a patient ’s quality of life,
9,10 but also pose a significant burden 
on healthcare facilities and the public and/or private payers who support these facilities .  Waycaster et al . 
noted a recent economic evaluation of Medicare beneficiaries which concluded that the United States spent a conservative estimate of $32B USD in 2014 on 8.2 million patients.
11  This equates to 
approximately $4,000 USD per patient.  
 Human amniotic membrane has been used in the treatment of wounds  since the early  20th century.
12  
Numerous potential applications of this tissue have been  investigated since then .  One noted application 
is for use in patients with DFU s.   A recent systematic review and meta -analysis  by Laurent et al. which 
aimed to “identify all relevant studies [using] search terms [such as] ‘diabetic foot ulcers’ OR ‘diabetic foot’ AND ‘amniotic membrane’ OR ‘amnion’ […] AND ‘standard therapy’ or ‘standard of care ’’’ identified 
seven (7) randomized  controlled trials involving these products.
13  This analysis demonstrated that 
“[h]uman amnion/chor ion membrane + standard of care treatment heals DFUs significantly faster than 
standard of care alone.”  Prior to this review, other s tudies demonstrated that amniotic membrane s have 
anti-inflammatory effects,12  are  antimicrobial,14 demonstrate  anti-scarring , maintain an anti -adhesive 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number  3.0  Page 15 of 59 
activity,12,15 are non-immunogenic with low antigenicity,14 have analgesic properties,16 and promote  re-
epithelialization.14,15,17 
 
AMNIOEXCEL  (AMNIOEXCEL, Integra LifeSciences Corporation, Plainsboro, NJ)  is a commercially available 
amniotic membrane allograft. The product is provided in multiple geometric configurations to be applied directly to clean, debrided wounds where bacterial burden and offloading have been addressed.  As one 
might assume, adequate vasc ular status and perfusion must also exist for DFUs to heal in a timely and 
orderly fashion.  
 In recent months, Integra LifeSciences has begun a limited marketing release of its AMNIOEXCEL Plus  
allograft which, unlike its predecessor, AMNIOEXCEL, retains the chorion layer of tissue and goes further to add another layer of amnion, thus creating an amnion -chorion -amnion sandwich.   
 AMNIOEXCEL Plus  is processed in compliance with US CFR Title 21 Part 1271 and Section 361 of the Public 
Health Service Act and regulated as a human cell and tissue product s (HCT/P). The base material for these 
products  is collected from live, healthy, planned cesarean section births of appropriately screened 
women, per American Association of Tissue Banks requirements. The collecte d placental tissue is then 
washed, dehydrated, cut, and packaged for commercial distribution.    
 Another allograft used in the treatment of DFU s is Apligraf (Organogenesis, Canton, MA).
3,18  The Apligraf 
allograft is a “living cell based product for chronic venous leg ulcers and DFU s. Apligraf is supplied as a 
living, bi-layered skin substitute.”4  Unlike the AMNIOEXCEL Plus products, the Apligraf product is not 
derived from amniotic tissue.   Apligraf is also a  HCT/P; however, it is registered with the FDA as a medical 
device.  
 Per the manufacturer’s website, “ Apligraf consists of living cells and structural proteins. A lower dermal 
layer combines bovine type 1 collagen and human fibroblasts (dermal cells), which produce additional matrix proteins. The upper epidermal layer is fo rmed by promoting human keratinocytes (epidermal cells) 
first to multiply and then to differentiate to replicate the architecture of the human epidermis. Apligraf does not contain melanocytes, Langerhans' cells, macrophages, and lymphocytes, or other struc tures such 
as blood vessels, hair follicles or sweat glands.   Apligraf is supplied as a circular disc approximately 75 mm 
in diameter and 0.75 mm thick. ” 
4 
 This study  is designed to com pare  clinically -relevant outcomes of subjects with DFU s who have been 
randomized to one of the following treatment cohorts : (1) AMNIOEXCEL Plus  in conjunction with SOC 
procedures ; (2) Apligraf in conjunction with SOC  procedures ; or (3) SOC procedures alone . 
 
 
 
  
[Intentionally Blank]  
 
 
  
 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number  3.0  Page 16 of 59 
2.3 RISK/BENEFIT ASSESSM ENT   
 
The presence of a DFU incurs certain risks .  Compared to people with diabetes  alone , those with 
diabetes and a foot ulcer have a 9 -fold greater risk for developing an infection, a 7 -fold greater risk 
of amputation, a 3. 5-fold greater risk of a fracture and  are more than twice as likely to fall.19  The 
longer the ulcer is open, the greater the chance for infection and amputation .20  Thus, the focus of 
care of the DFU  is to close the wound as quickly as possible.  
 
2.3.1  KNOWN  POTENTIAL RISKS  
 
AMNIOEXCEL Plus  
 
AMNIOEXCEL Plus is intended for use as a wound covering.  This product is an allograft 
tissue intended for homologous use for the repair, reconstruction, and replacement of skin 
at the direction of a physician.   
 AMNIOEXCEL Plus  contains trace amounts of ethanol.  It sh ould be not used in patients with 
known sensitivity to ethanol.  
 In order to reduce the risk of complications, AMNIOEXCEL Plus  should not be used in the 
presence of active infection.  
 Although donor tissue is evaluated and processed following strict FDA guidelines, the donor screening methods are limited and may not detect all diseases.  As with any allograft, 
complications at the graft site may occur post -operatively (i.e., post -application) that are 
not readily apparent.  These include, but are not limite d to: 
• Transmission of communicable diseases, including those of unknown etiology 
• Transmission of infectious agents such as viruses, bacteria, and fungi  
• Immune reaction of, or allergic reaction to, implanted HCT/P  
 
Apligraf 
 
Apligraf is indicated for use wi th standard DFU  care for the treatment of full- thickness 
neuropathic DFU s of greater than three weeks’  duration which have not adequately 
responded  to conventional ulcer therapy and which extend through the dermis but without 
tendon,  muscle, capsule or bone exposure.  
 
The following are adverse events  (AEs)  reported in greater than 1.0% of Apligraf patients in 
a DFU s tudy conducted by the manufacturer.  
10-20% of Subjects  
• Neuropathic ulcer (non -study site)  
• Suspected wound infection (non -study site)  
• Non -neuropathic skin alteration (non- study site)  
• Suspected wound infection (study site)  
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date  05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number  3.0  Page 17 of 59 
5-10% of Subjects  
• Cellulitis (non- study site)  
• Cellulitis (study site)  
• Osteomyelitis (non -study site)  
• Vesicular bullous rash (non -
study site)  
• Pain (overall body  • Fungal infection (non -study 
site)  
• Hypoglycemia  
• Infection (overall body  
• Hematoma (non -study site)  
 
<5% of Subjects  
• Deteriorating ulceration (study 
site)  
• Rash (non- study site)  
• Non -neuropathic skin 
alteration (study site)  
• Pain (non -study site)  
• Bone dislocation (non -study 
site)  
• Peripheral edema  
• Accidental Injury (overall body  
• Accidental Injury (non -study 
site)  
• Fever (overall body  
• Hyperglycemia   
• Dry skin (non -study site)  
• Chest pain  
• Bronchitis  
• Osteomyelitis (study site)  
• Nausea  
• Pharyngitis  
• Anemia  
• Right Heart failure  
• Abscess (study site)  
• Urinary tract infection Deteriorating ulceration (non -
study site)  
• Gastroenteritis  
• Cataract  • Abscess (overall body  
• Gastritis  
• Spontaneous bone fracture  
• Diarrhea  
• Positive Wound Culture (study site)  
• Arthrosis (non- study site)  
• Malaise  
• Rash (study site)  
• Hematoma (study site)  
• Gangrene (non -study site)  
• Dyspepsia  
• Accidental Injury (study site)  
• Infection (non -study site)  
• Gangrene (study site)  
• Spontaneous bone fracture (non- study site)  
• Viral infection  
• Back pain  
• Angina  pectoris  
• Arteriosclerosis  
• Cardiomegaly  
• Gastrointestinal carcinoma  
• Colitis  
• Rhinitis  
• Arthritis  
• Confusion  
 Apligraf is contraindicated for use on clinically infected wounds.  
 Apligraf is contraindicated in patients with known allergies to bovine  collagen. 
 Apligraf is contraindicated in patients with a known hypersensitivity to the components of the A pligraf agarose shipping medium  listed below : 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 18 of 59 
o agarose,  
o L-glutamine,  
o hydrocortisone,  
o human recombinant insulin,  
o ethanolamine,  
o O-phosphorylethanolamine,  o adenine,  
o selenious acid,  
o DMEM powder,  
o HAM’s F- 12 powder,  
o sodium bicarbonate,  
o calcium chloride  
Standard of Care  (SOC)  Treatment  
 
SOC consists of: 1) moist wound dressings, 2) debridement of necrotic/non -viable tissue, 3) 
infection surveillance and management and 4) offloading  of weight bearing from vicinity of the 
ulcer.  
 In this study, the moist wound dressings include normal saline gel which is then covered with a non -
adhesive foam and secured with conforming roller gauze and dressed with Coban.  
The risks of SOC  procedures are as follows:  
Use of Wrap and Bandages  
Tightness - Some subjects may experience a sense of tightness after the study doctor 
or staff apply the bandages over the treatment area.   
Contact Dermatitis - Some subjects may experience a localized skin reaction to the 
bandages  
Use of the offloading boot  
Imbalance – Some subjects may have initial or long -term difficulty w alking with the 
offloading boot.  
Restriction of activities/movement – Some subjects may experience an inability or 
reduction in ability to do things that they were once able to do (i.e., wear shoes on the 
foot, ambulate, etc.)  
 
Debridement Procedure  
The risks associated with the debridement procedure are as follows:  
  
• Pain - Most patients will experience pain either during or after the debridement procedure.  
• Bleeding – Most patients will experience bleeding of the ulcer after debridement  
• Infection - Few patients will develop an infection after debridement  
• Delayed Healing - Few patients will develop delayed healing of the ulcer after debridement  
• Loss of Healthy Tissue – Few patients will experience removal of healthy tissue in addition 
to removal of dead tissue.  
 
Reaction to topical or local anesthesia (if used) – Few patients will experience a reaction to topical 
or local numbing agents used to decrease pain prior to debridement.   
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 19 of 59 
Hemoglobin A1c Test  (Finger stick  or Blood Draw)  
The risks associated with the h bA1c procedure are as follows:  
 
• pain  
• bruising  
• dizziness  
• infection  
 
Vascular Perfusion Tests  
 
Risks of Measuring the Ankle -Brachial Index  
• Pressure/Discomfort around the arm and/or the leg – Most subjects who have this test 
performed will experience pressure and discomfort from the blood pressure cuff that is 
applied to either the leg or arm.  
• Bruising – Some subjects may experience bruising from the blood pressure cuff  
 
Risks of Taking Toe Pressure  
• Pressure/Discomfort around the big to e – Some subjects who have this test performed will 
experience pressure and discomfort from the cuff.  
 
Risks of Measuring Transcutaneous Oximetry  
• Contact Dermatitis - Some subjects may experience a localized skin reaction to the gel used 
with the probes that will be applied to the skin for this test.  
 
2.3.2  KNOWN POTENTIAL BENE FITS  
 
A recent meta -analysis noted that some patients who use tissue- based allografts heal sooner than 
those who undergo SOC procedures alone.13   However, b ecause this is the first clinical trial using 
AMNIOEXCEL Plus in the management of DFU s, improved outcome for subjects in this group 
cannot be guaranteed.  
 Subjects in this study may undergo more rigorous and/or more frequent treatments compared to their non -study counterparts.  This may assist in the entire study population’s prognosis, although 
it cannot be guaranteed.  
   
[Intentionally Blank]  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 20 of 59 
3 OBJECTIVES AND ENDPO INTS  
Table 3: Objectives and Endpoints  
OBJECTIVES  ENDPOINTS  
Primary   
The primary objective of this study is to 
compare outcomes associated with the 
use of AMNIOEXCEL Plus Placental 
Allograft Membrane, Apligraf living, bi-
layered skin substitute and SOC  in the 
management of DFU s.   The primary endpoint of this study is the incidence of complete 
wound closure, as assessed by the Investigator at or before 
Week 12 of the Treatment Phase and confirmed 2 weeks later .  
Confirmed complete wound closure is defined as complete 
skin re -epithelialization that is without drainage or dre ssing 
requirements . 
Secondary   
1. Determine the proportion of subjects 
in each study arm with complete 
closure of the study ulcer at or before 12 weeks of treatment  1. Proportion of subjects with complete closure of the study 
ulcer at or before Week 12  and confirmed 2 weeks later as 
assessed by computerized planimetry.  
2. Proportion of subjects with complete wound closure of the study ulcer at or before Week 12  and confirmed 2 weeks 
later as assessed by independent, blinded, assessment of 
photographs.  
2. Determine the time to complete 
wound closure in each study arm 1. Time to complete wound closure, as assessed by the 
Investigator.  
2. Time to complete wound closure, as assessed by 
computerized planimetry.  
3. Determine the rate of wound closure 
in each study arm  1. Rate of wound closure, as assessed by computerized 
planimetry.  
4. Assess medical resource utilization 
outcomes in each study arm  1. Medical resource utilization associated with treatment of 
DFU and related complications as determined by a 
comparison of estimate d costs from the presumed billing 
codes which would have been used for each patient.  
Exploratory   
1. The proportion of subjects in each 
cohort whose wounds are closed at 4 
weeks of treatment.  1. Wound closure status at Week 4 of Treatment  
2. The effect of any covariate on the 
primary endpoint.  1. Co-variate analyses of the primary endpoint using those 
listed in section 9.3.  
Safety Endpoints   
The safety objective of this study is to 
assess adverse events associated with 
either of the study treatments and/or all study procedures in the management of 
DFU s. Incidence of all treatment, procedure, and/or wound -related 
adverse events or serious adver se events  in any of the study 
cohorts . 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 21 of 59 
 
4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
This is a prospective, multicenter, parallel- group, randomized, three -arm trial designed to assess 
the proportion of ulcers achieving complete wound closure  and confirmed 2 weeks later in a 
population with adequate arterial circulation, following up to 11 weeks of either AMNIOEXCEL Plus  
Placental Allograft Membrane with SOC , Apligraf bi-layered skin substitute with SOC , or SOC  alone.   
 Subjects will be rando mized 1:1:1  to receive  one of the following : 
 
• AMNIOEXCEL Plus Placental Allograft Membrane with SOC 
 
• Apligraf bi-layered skin substitute with SOC  
 
• SOC alone  
 
4.2 SCIENTIFIC R ATIONALE FOR S TUDY DESIGN  
 
Prospective, multicenter, randomized studies provide the  most  objective methods for analyzing 
the outcomes of multiple treatment groups.   The use of a three-cohort study allows simultaneous 
comparison of the treatment in question utilizing an active comparator and current SOC , the true 
baseline.   
 
4.3 JUSTIFICATION FOR INVESTIGATIONAL PROD UCTS /TREATMENTS  
 
While there may be generalizable evidence that all tissue- based allografts outperform SOC  
therapies in the management of DFU s, the performance of specific products varies.  Although there 
is evidence that AMNIOEXCEL Amniotic Allograft Membrane outperforms SOC  procedures
1,21– 23, 
AMNIOEXCEL Plus Placental Allograft Membrane has not been assessed  as an advanced wound 
therapy for DFU s. 
 
The comparator treatment, Apligraf, has been investigated as an advanced treatment for patients 
with DFU s and has  been compared to SOC procedures.3,18,24 
 The use of an offloading boot is a known and widely used SOC  adjunctive therapy .  Clinical studies 
have shown that offloading with rigid boots provide a more aggressive healing rate as compared to shoes, custom insoles, w heelchairs, bedrest, and/or crutches.
25  The use of a boot in this clinical 
trial, in addition to moist wound dressings , will p rovide the most robust baseline to compare the 
active treatments (i.e., Investigational products) against. 
 4.4 END OF S TUDY DEFINITION  
The study is considered completed after all of the screened  and enrolled (i.e., randomized ) subjects 
have completed all of their study treatments  and been signed off by the investigative sites in the 
electronic data capture ( EDC) system .
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 22 of 59 
5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
All of the following criteria must be met  by a potential subject to be enrolled in the study.  The 
subject must:  
1. Have participated in the informed consent process and signed a study -specific informed consent 
document.  
2. Be able and willing to comply with study procedures , including study visits, study dressing 
regimens, and compliance with study required offloading  device . 
3. Be ≥ 21 years of age.  
4. Have Type I or Type II diabetes mellitus with Investigator -confirmed glycosylated hemoglobin 
(HbA1c) of ≤ 12% within 3 months prior to screening visit.  
5. Have at least one diabetic foot ulcer that meets ALL of the following criteria: 
• Ulcer has been in existence for a minimum of four weeks prior to signing the Informed Consent Form for trial participation but no more than 12 months  
• Ulcer is a partial or full thic kness diabetic foot ulcer without capsule/tendon/bone 
exposure (Wagner Grade 1 or superficial 2).   
• Ulcer is located on the foot or ankle (with no portion above the top of the malleolus, i.e., proximal to the malleolus).   
• If the subject has more than one ulcer that meets the eligibility criteria, the ulcer designated as the study ulcer will be at the discretion of the Investigator.   
• There is a minimum 1 cm margin between the qualifying study ulcer and any other ulcer on that same foot, post- debridement.  
6. Ulcer size (i.e., area) is > 1 cm2 and < 12 cm2 post -debridement at Screening Visit 1 and 
Randomization (Day 0).  
7. Have adequate vascular perfusion of the affected limb as defined by at least one  of the 
following:   
• Ankle -Brachial Index (ABI) ≥ 0.65 or ≤1.2, p erformed within 3 months  of screening  visit 1   
• Toe pressure (plethysmography) >50 mmHg at time  of screening visit 1 , 
• TcPO 2 >40 mmHg at time  of screening  visit 1  
8. Be willing and able (or have a family member/friend willing and able) to apply required applicable dressing changes as well as study -required offloading/protective device if and when 
applicable . 
 
5.2 EXCLUSION CRITERIA  
 
Potential subjects will not be enrolled in the study if any of the following  criteria are m et: 
1. The subject was previously randomized and treated under this clinical study protocol.   
2. The study ulcer has:  
a. Unexplored tunneling,  
b. Undermining and/or  
c. Sinus tracts  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 23 of 59 
that necessitates surgical operating -room debridement and/or penetrates to 
capsule/tendon/bone .  
3. The subject has a known sensitivity to ethanol.  
4. The subject has a known allergy to bovine collagen.  
5. The subject has a known hypersensitivity to any of the components of the Apligraf agarose 
shipping medium listed below:  
o agarose,  
o L-glutamine,  
o hydrocortisone,  
o human recombinant insulin,  
o ethanolamine,  
o O-phosphorylethanolamine,  
o adenine,  
o selenious acid,  
o DMEM powder,  
o HAM’s F- 12 powder,  
o sodium bicarbonate,  
o calcium chloride  
6. The subject has a known sensitivity to any of the SOC materials which com e in contact with the 
skin:  
o Coban™  
o Conforming gauze  
o Optifoam® non -adhesive dressing 
o Normal Saline (liquid or gel)  
o Cotton Gauze  
o Normal saline (liquid & gel)  
o Non -adhering dressings  
o Steristrip s 
7. The subject is unable to safely ambulate with the use of a study required offloading boot.  
8. The subject has suspected or confirmed gangrene or wound infection of the study ulcer, as evidenced by tissue necrosis, redness, pain, and/or purulent drainage and/or receiving systemic antibiotics for the treatment of such.  
9. The subject has suspected or confirmed osteomyelitis of the foot with the study ulcer.   
10. The subject has participated in another clinical trial involving a device or an investigational study drug/treatment within 28 days of randomization.  
11. In the opinion of the Investigator, the subject has received, within 28 days of signing the Informed Consent Form, or is scheduled to receive during study participation, a medication or 
treatment which is known to interfere with or affect the rate and quality of wound healing ( e.g., 
systemic steroids, immunosuppressive therapy, autoimmune disease therapy, dialysis, 
radiation therapy to the foot, vascular surgery, angioplasty, or thrombolysis).  
12. The subject has a history of bone cancer or metastatic disease of the affected limb, radiation therapy to the foot, or has had chemotherapy within the 12 months prior to signing the Informed Consent Form for trial participation.  
13. The subject is currently pregnant or is actively trying to conceive.  (Patient statement confirming lack of pregn ancy is sufficient.)  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 24 of 59 
14. In the opinion of the Investigator, the subject is unable to comply with the treatment regimen 
(i.e., return for clinic visits, perform required dressing changes and use study -designated 
offloading  device[ s]).  
15. In the opinion of the In vestigator, the subject has a history of, or is currently diagnosed with, 
any illness or condition, other than diabetes, that could interfere with wound healing (e.g., end -
stage renal disease, severe malnutrition, liver disease, aplastic anemia, Raynaud’s Syndrome, connective tissue disorder, acquired immune deficiency syndrome, HIV positive, or sickle cell anemia).  
16. In the opinion of the Investigator, the subject has unstable Charcot foot or Charcot with bony prominence that could inhibit wound healing.  
17. The subject has ulcers secondary to a disease other than diabetes (e.g., vasculitis, neoplasms, 
or hematological disorders). 
18. In the opinion of the Investigator, the subject has excessive lymphedema that could interfere with offloading and/or wound healing.  
19. The study ulcer has received wound dressings that include growth factors, engineered tissues, or skin substitutes within 28 days of randomization or is scheduled to receive treatment during the study (e.g., PriMatrix, AMNIOEXCEL (first generation), Regrane x, Dermagraft, EpiFix, 
GraftJacket, OASIS, Omnigraft, or Integra BMWD).  
20. The study ulcer closed more than 30% in area, post -debridement , between Screening Visit 1 and 
Randomization (Day 0, as measured by planimetry).  
5.3 LIFESTYLE CONSIDERAT IONS  
 
Similar to patients experiencing SOC  procedures outside of this study, s ubjects  in this study will 
have to:  
o Wear an offloading boot.  This may cause subjects to ambulate with a limp  or may reduce 
the subject’s ability to perform activities they are used to doing (e.g., walk upstairs, go outside, etc.)  
o Change dressings on a daily basis  when in the Screening Period and if randomized to the 
SOC cohort .  This may add time to a subject’s daily grooming regimen.  
 All of these activities are similar to treatments /procedures that occur outside of this study and 
would occur whether or not this subject was included in the study.  
 
5.4 SCREEN FAILURES  AND RESCREENING  
 Screen failures are defined as subjects  who consent to participate in the clinical trial but are not 
subsequently randomized  to a study intervention . A minimal set of information is required to ensure 
transparent reporting of screen failure subject s, to meet the Consolidated Standards of Reporting Trials 
(CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event s 
(SAE).  
 Individuals  who do not meet the criteria for participation in this trial (scree n failure) because of inability 
to attend second screening visit, recent participation in a former clinical trial, or remission of exclusionary cancer status as described in the exclusion criteria may be rescreened  once . Rescreened subject s will be  
assigned a different  subject  number from the one designated at the initial screening.  
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 25 of 59 
The enrollment and screening flow chart of activities can be seen in figure 2.  NOTE: Patients who enter 
the Screening Period will also be designated as a screen fail if they withdraw consent.  
 
 
 
 
  
 
Screening Visit 2  
(-1 Week ± 3 Days)  
Screening Visit 1  
(-2 Weeks ± 3 Days)  
All Potential Subjects  
Inclusion/Exclusion  
Met  
 Not Met  
Screen 
Fail 
Inclusion/Exclusion  
Met  
 Not Met 
Screen 
Fail 
Randomization Visit  
(Days 0)  
Inclusion/Exclusion  
Met  
 Not Met  
Screen 
Fail 
Ulcer Size Decreased >30%  
 Ulcer Size Did Not Decrease >30%  
Randomize  
(Enroll)  
AMNIOEXCEL® Plus + 
Standard of Care  
Apligraf® +  
Standard of Care  
Standard of Care  
Figure 2: Screening Flow of Activities  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 26 of 59 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
RECRUITMENT  
Pre-screening activities for this study should include identification of potential subjects that meet 
the following general criteria.   
 
• Age ≥ 21 years ,  
• a diagnosis of diabetes and  
• presence of DFU . 
 
Note: pre -screening activities should never include the  collection of study -related information or 
protected health information (PHI) . 
 
Advertisements are not prescribed for this study , per se ; however, Integra may approve site-
specific advertisements if warranted.  Any site -specific advertisements must be approved by both 
the Sponsor and the site’s Institutional Review Board prior to distribution to outside parties.  
 
RETENTION  
 Investigators and site staff should make every effort to retain enrolled subjects and redu ce loss-to-
follow -up.  The following methods should be employed in order to prevent subject loss: 
• Ensure complete understanding of the roles and responsibilities of the study subject .  This can 
be achieved with a thorough informed consent process.  
• Make follow -up appointments far in advance  
• Develop a strong rapport with study subject s, offer flexible appointment times, and ensure 
strong PI involvement  
 
 
 
    
[Intentionally Blank]  
  
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 27 of 59 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION S ADMINISTRATION  
 6.1.1  STUDY INTERVENTION  DESCRIPTION S 
6.1.1.1  INVESTIGATIONAL PRODUCTS (to be used with SOC  products ) 
AMNIOEXCEL Plus  
AMNIOEXCEL Plus tri-layer Placental Allograft Membrane ( T-PAM) is a minimally 
manipulated placental membrane product made from tissues donated by pre -screened 
mothers during planned C -sections.   AMNIOEXCEL Plus is intended for use as a wound 
covering.  This product is an allograft tissue intended for homologous use for the repair, 
reconstruction, and replacement of skin at the direction of a physician.  
More information can be found in the supplied Instructions for Use document that is 
included with the AMNIOEXCEL Plus  product.  
In this study, AMNIOEXCEL Plus will be applied weekly, in conjunction with SOC, as long 
as the ulcer remains open, or up to and including Week 1 1, whichever comes first.   Note: 
In order to reduce the risk of complications, AMNIOEXCEL Plus should not be used in the 
presence of active infection.  See Section 7.1 for instructions on treating infections as part 
of this trial.  
Apligraf 
Apligraf is a living, bi- layered skin substitute: the epiderm al layer is formed by human 
keratinocytes and has a well- differentiated stratum corneum; the dermal layer is 
composed of human fibroblasts in a bovine Type I collagen lattice. While matrix proteins and cytokines found in human skin are present in Apligraf,  Apligraf does not contain 
Langerhans cells, melanocytes, macrophages, lymphocytes, blood vessels or hair follicles.  
Cells used in the manufacture of Apligraf are processed under aseptic conditions. The cells are originally derived from donated human neonatal male foreskin tissue. The foreskin donor’s mother is tested and found negative for human viruses, including antibodies to 
Human Immunodeficiency Virus Types 1 and 2 (HIV -1 and HIV -2), Human 
Immunodeficiency Virus Type 1 (HIV -1), human T -lymphotropic virus types 1  and 2 (HTLV -
1 and HTLV -2), Hepatitis A Virus (HAV), H epatitis B Virus (HBV),  Hepatitis B Surface 
Antigen (HbsAg), H epatitis C Virus (HCV), W est Nile Virus (WNV), Epstein -Barr V irus (EBV), 
Cytomegalovirus (CMV), and S yphilis. The  fibroblast and keratinocyte cell banks which are 
the source of the cells from  which Apligraf is derived are tested for human and animal 
viruses,  retroviruses, bacteria, fungi, yeast, mycoplasma, karyology, isoenzymes, and  
tumorigenicity. The final product is tested for morphology, cell viability,  epidermal 
coverage, sterility, mycoplasma, and physical container integrity.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 28 of 59 
Product manufacture also includes reagents derived from animal materials  including 
bovine pituitary extract. All animal derived reagents are tested fo r viruses, retroviruses, 
bacteria, fungi, yeast, and mycoplasma before use.  Bovine materials are sourced to 
minimize bovine spongiform encephalopathy  (BSE).  
Apligraf is also indicated for use with standard DFU  care for the treatment of full -thickness 
neuropathic DFU s of greater than three weeks’ duration which have not adequately 
responded to conventional ulcer therapy and which extend through the dermis but 
without tendon, muscle, capsule or bone exposure.  
More information can be found in the supplied Prescribing Information that is included with the Apligraf product.  
In this study, Apligraf will be applied weekly, in conjunction with SOC , as long as the ulcer 
remains open, or up to and including Week 11, whichever comes first.  Note: In order to 
reduce the risk of complications, Apligraf should not be used in the presence of active infection.  See Section 7.1 for instructions on treating infections as part of this trial.  
CON TROL PRODUCTS (i.e., SOC) 
The control treatment reflects SOC  appliances and materials:  
• Coban™  
• Conforming gauze  
• Optifoam® non -adhesive dressing 
• Cotton Gauze  
• Normal saline (liquid or gel)  
• Non -adhering dressings  
• Steristrips  
• An offloading  boot ( Pneumatic Short  Leg Walker), as appropriate  
6.1.2  UTILIZATION AND ADMI NISTRATION  
 
IMPORTANT: These recommendations are designed only to serve as a general guideline.  They 
are not intended to supersede institutional protocol or professional clinical judgement 
concerning patient care.  
6.1.2.1  RECOMMENDED INSTRUCTIONS FOR USE OF THE PNEUMATIC SHORT LEG WALKERS  
(BOOT ) & SUPPLIES ( SOC DRESSINGS)  
During the Screening Phase of the study, all subjects will have SOC  products applied by the 
investigative site  at the weekly visits.   They will be then instructed on how to change their 
dressings on a daily basis.  After randomization, only subjects who are randomized to  the SOC 
cohort will continue daily dressing  change s.  Those subjects in either the AMNIOEXCEL Plus or 
Apligraf cohorts will only have their dressings changed weekly at follow -up visits until the 
investigator determines that their wound has closed.   If the wound closes on or before week 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 29 of 59 
12, offloading  (if previously utilized for that subject)  will continue without  dressings during the 
follow -up period.  
 
The
 off-loadin
g boot /protective device and SOC  dressings to be used in this study will be 
provided by the Sponsor through a specific distributor.   The off -loadin
g boot /protective device 
will only be used by subjects who require offloading throughout the Screening and Treatment 
(i.e., those subjects with study ulcers located on the plantar or lateral surfaces of the foot or any location experiencing weight
-bearin
g or shear forces as determined by the Investigator ). 
These subjects will wear the boot up to their exit from the study.   The boot will be applied to 
the subject’s foot on top  of the dressings.  
 
Application of the dressings & boot  by the Investigator : 
 1. Gently remove any dressing previously applied to the wound and clean the area with a 
gentle cleanser.  
2. If appropriate, debridement and hemostasis will be performed.   (Note: in this study only 
sharp debridement will be used)  
3. During Screening and for SOC -randomized subjects: Instruct the subject on the proper way 
to change dressing  
a. Inspect the wound and perform study assessments as directed elsewhere  
4. Apply normal saline gel to the thickness of a coin.  
5. Cover the gel with a foam dressing.  
6. Secure the foam dressing  with conforming roller gauze.  
7. Cover the roller gauze with Coban.   
8. For subjects who have ulcers that require offloading, apply the boot.  
 
Daily Changing of the Dressings by the Subject : 
 
1. Remove boot, if applicable  
2. Gently r emove dressings 
3. Clean the wound with tap water and pat the area dry  
4. Inspect the wound  
a. Subject will contact the site by phone if they believe there is anything wrong with the wound.  
5. Apply normal saline gel to the thickness of a coin.  
6. Cover  the gel with a foam dressing.  
7. Secure the dressings with conforming roller gauze.  
8. Cover the roller gauze with Coban.   
9. For subjects who have ulcers that require offloading, apply the boot.  
 
Note: Subjects who use the offloading boot will be instructed that it is to be worn at all times  
except when bathing or sleeping.  
  
 
   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 30 of 59 
6.1.2.2  RECOMMENDED INSTRUCTIONS FOR USE OF AMNIOEXCEL PLUS  
 
Preparation Instructions (also found in the product’s Instructions for Use supplied with the 
product):  
1. Open carton or box containing AMNIOEXCEL Plus  and remove the peel -pack. 
2. Peel open the outer package and remove the inner foil pouch using aseptic technique. Note: The inner foil pouch and its contents are sterile and may be placed directly into the sterile field.  
3. Peel the inner pouch open and place the AMNIOEXCEL Plus  into the sterile field. Note: 
Application of AMNIOEXCEL Plus will be easier if the surface  to be covered is relatively 
dry. 
4. Either side of the membrane may be applied to the wound surface.  
5. It is somet imes necessary to gently “roll” the AMNIOEXCEL Plus  at the edges to smooth 
out wrinkles and folds that can occur during placement.  
6. Secure the AMNIOEXCEL Plus , when necessary, using the physician ’s choice of fixation  
(Steri -strips are provided) . 
7. Cover the AMNIOEXCEL Plus product with the non -adherent dressing 
8. Optional: A saline -moistened bolster dressing is applied to ensure full contact with the 
wound bed.  
9. Proceed with SOC dressings as described earlier.  
 
Additional training will be supplied by an Integra team member  either via onsite training or 
video conference .  Important note: Subject records must be maintained for the purpose of 
track ing tissue post -transplant per The Joint Commission on Accreditation of Healthcare 
Organizations and FDA requirements.  The AMNIOEXCEL Plus  ID number must be recorded in the 
recipient’s medical record.  Patient labels which include tissue numbers are contained in the AMNIOEXCEL Plus  package to aid in the tracking process.  
 
In this study, the AMNIOEXCEL Plus will be covered with a non -adherent dressing and a saline 
moistened bolster applied, when appropriate, to ensure that the AMNIOEXCEL Plus is maintained with intimate contact to the wound bed.  A foam dressing will be applied to cover the bolster and the dressings secured with conforming roller gauze.  Finally, a cover dressing of Coban will be applied.  
 
The dressing should be kept dry and will be changed once weekly during study visits.  The 
subject will be instructed on t he signs that indicate a need to seek medical attention.  
 
6.1.2.3  RECOMMENDED INSTRUCTIONS FOR USE OF APLIGRAF26 
 
More information about application of the product can be found on manufacturer’s website:  
http://www.apligraf.com/professional/what_is_apligraf/how_is_it_applied/index.html   
 1. Wound Bed Preparation:  
• When applying Apligraf there should be no signs of infection  (see Section 7.1 for 
subjects who become infected during the course of the study).  
• The wound bed should be prepared with appropriate method of debridement  
2. Placement of the Apligraf®  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 31 of 59 
• If desired, fenestrate Apligraf® with a knife blade or mesh (1.5 -1 ratio). Apply Apligraf 
to wound and affix with method of preference i.e.,  Steri -Strips™, wound glue at 
periphery, or sutures  
3. Primary Dressin g 
• Cover Apligraf® with primary non -adherent dressing  
4. Secondary Dressing  
• Apply appropriate dressing determined by wound type. A non -cytotoxic antimicrobial 
may also be applied at this time.  
• Provide Offloading  for DFU 
• Keep dressing dry until first follow -up appointment.  
5. First Follow -up 
• At Week 1  follow up, remove secondary dressing only for wound inspection and 
evaluation. Primary dressing (non -adherent) should be left undisturbed to facilitate 
integration of Apligraf®.  
6. Application of Secondary Dressing 
• Reap ply appropriate secondary dressings  
7. Subsequent Follow -ups 
• On second follow up (14 days , Week 2 ), remove secondary and primary dressing for 
wound inspection and evaluation. Do not disturb or debride the wound bed. Perform  
light normal saline wash  
8. Applicatio n of Primary and Secondary Dressings  
• Apply new primary (shown) and secondary dressings  
• On subsequent weekly follow -ups, continue to change primary and secondary dressings 
to monitor wound healing.  
• Apligraf may be reapplied if needed until wound healing is complete, as shown.  
Additionally, the site should refer to Apligraf’s Instructions for Use documents that are 
supplied with the product and/or consult an Apligraf representative for appropriate 
training.   
 
6.2 HANDLING/ STORAGE  
AMNIOEXCEL PLUS  
AMNIOEXCEL Plus Placental Allograft Membrane is provided in prescribed multiple geometric 
configurations.  AMNIOEXCEL Plus Membrane is dehydrated during processing and should be 
visibly dry when the package is opened.  The inner peel pouch and tissue produ ct are terminally 
sterilized via E -beam irradiation and may be placed directly into the sterile field.  Included in the 
packaging along with this insert are a Tracing Record and a set of patient labels.   
• AMNIOEXCEL Plus is sterile and packaged for single patient, one time use only.  
• Once opened, AMNIOEXCEL Plus must be used immediately or discarded.  
AMNIOEXCEL Plus is to be stored in a clean, dry location at room temperature.   
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 32 of 59 
APLIGRAF  
The site should refer to Apligraf’s Instructions for Use documents that are supplied with the 
product and/or consult an Apligraf representative for information on appropriate handling and storage of the product.  
CONTROL/STANDARD OF CARE SUPPLIES  
All supplies for the SOC  procedures can be kept at room temperature.   General adherence to 
product expiration dates should be undertaken.  
6.2.1  ACQUISITION AND ACCOUNTABILITY  
 
Sites will be supplied by Integra with AMNIOEXCEL Plus  and the SOC  materials (i.e., boot, gauze , 
Coban, etc.) to be used with each of the investigational products .  Specifically, sites will be 
provided with:  
• Daily dressing kits used at home by all  subjects during the Screening Phase of the study 
and if the subject is  subsequently  randomized to the SOC cohort.   
• Weekly dressing kits used by the investigator on all subjects during the Treatment Phase 
of the study.  
Important note: Subject records must be maintained for the purpose of track ing tissue post -
transplant per The Joint Commission on Accreditation of Healthcare Organizations and FDA requirements.  The AMNIOEXCEL Plus  ID number must be recorded in the recipient’s medical 
record.  Patient labels which include tissue numbers are contained in the AMNIOEXCEL Plus  
package to aid in the tracking process.  
 Sites will purchase Apligraf from the manufacturer and order for arrival the day prior to the 
projected randomization date for every  subject in the event that the subject is randomized to the 
Apligraf product.  This purchase will be reimbursed by Integra.    
 
 
Sites will document the use of all study product s in the subject’s medical records, in  the required 
electron ic case report forms ( eCRFs ), any applicable study logs .   
 6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  AND BLINDING  
 This study will use  randomization to minimize bias  in this open label study .  Randomization will 
occur in a 1:1:1 ratio and use  a mixed block  methodology .  No blinding is possible .  As well, no 
analytical blinding will occur during data review and/or analysis.  
 
6.4 STUDY INTERVENTION  COMPLIANCE  
 
Subject  compliance will be assessed by the site via standard didactic and interview methods.  An 
initial training on dressing changes and application of the boot with the subject will occur on 
Screening Visit 1 ( -12 weeks ± 3 days).  Compliance and subsequent (i. e., refresher) training will 
occur on each follow -up visit until the patient completes the study.  This is shown in detail in the 
Table 2: Schedule of Activities.  
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confidential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 33 of 59 
6.5 CONCOMITANT THERAPY  
 
Local Anesthesia (as required)  
 
Debridement will be performed when appropriate on any study visit, at the discretion of the 
investigator. Debridement involves the use of a scalpel or other sharp implement to remove all 
dead and dying tissue on and around the ulcer .  Debridement may involve the use o f local 
anesthetics to reduce the possibility of pain the subject may feel  during this procedure .  The use 
of topical anesthetics is  forbidden in this study.  
 
All anesthetics should be documented on the Concomitant Medications eCRF.  
 
NO other therapies such as devices, grafts, or medications which are intended to improve wound 
healing  are permitted to be used on enrolled subjects . 
          
[Intentionally Blank]  
  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 34 of 59 
7 STUDY INTERVENTION DISCONTINUATION AND SUBJECT  
DISCONTINUATION/ WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTI ON 
 
For Subjects Who Develop an Infection:  
 
Subjects who, during the course of the Treatment Phase, develop clinical signs and/or symptoms of infection ( e.g.,  erythema, edema, pain, inflammation, increased drainage etc.) and in the opinion of 
the Investigator, require oral antibiotic therapy may receive a single course  of oral antibiotics during 
the Treatment Phase of the study.  Should a second consecutive cour se be required/desired, the 
subject will be exited from the study.  This antibiotic therapy will be noted on the Concomitant 
Medications eCRF.  
 In addition to the above, for those subjects receiving Apligraf or AMNIOEXCEL Plus and develop signs/symptoms of  infection, application of those allografts will be withheld on that visit. 
Application of allografts may be withheld for no more than 1 week at a time and no more than twice (non- consecutive visits) during the 12 -week Treatment Phase.  If signs and sympto ms of infection 
requiring antibiotic therapy persist for more than one visit, or appear on more than 2 non -
consecutive visits during the Treatment Phase, the subject will be discontinued from study participation.  
 For Subjects Whose Wound Closes : 
 Discontinuation from treatment in any of the study cohorts  does not mean discontinuation from 
the study.   There is one scenario in which a subject may continue in the study after intervention is 
final:   
 
After treatment with AMNIOEXCEL Plus , Apligraf, and/ or SOC AND  if the subject’s wound 
is documented as closed  at or before week 12 , the subject will continue to be monitored 
for two weeks to confirm wound closure .  This is noted as week 13 and 14 in the Schedule 
of Activities, above, but may occur earlier. 
 If the subject’s wound has NOT closed by  week 12, the subject will be considered a study failure and 
will not have any further study visits . 
 
 7.2 SUBJECT DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
 
Subjects are free to withdraw from participation in the study  at any time upon request.   As well, an 
investigator may discontinue or withdraw a subject  from  the study for the following reasons : 
• If the subject’s wound is open at follow -up week 1, the subject will be exited.  They will be 
noted as having completed their study requirements.  
• Significant study intervention non -compliance  
• If any adverse event (AE), laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the subject  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 35 of 59 
• Anytime continued participation in the study is not in the best interest of the subject  
• Disease progression which requires discontinuation of study participation  
• Signs/symptoms of infection which require antibiotic therapy that persist more than 1 visit at 
a time or more than twice (non -consecutive visits) during the 12 -week Treatment Phase.  
• If the subject  meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
• If the subject’s si te withdraws from the study  
• If the Sponsor decides to stop the study  
The reason for subject discontinuation or withdrawal from the study will be recorded on the 
appropriate  eCRF .  Subjects who sign the informed consent form and are randomized but do not 
receive the study intervention may be replaced.   
7.3 LOST TO F OLLOW-UP 
  
If a subject does not return for a study -related visit, the subject is not automatically considered lost -
to-follow -up (LTFU).  The site should proceed with the  following prior to designating a subject as 
LTFU:  
1. Contact the subject via phone  
a. Use the primary phone; if the subject’s phone has been disconnected utilize any other phone numbers ever provided.  
b. Contact the subject’s Primary Healthcare Physician for any contact information  
2. Contact the subject via certified mail  
a. Send a certified letter to the subject’s most recent address.  
 
Only after the subject fails to respond to the certified letter may the subject be considered  LTFU.   
 
Subjects who are discontinued, lost -to-follow -up or withdrawn and who have not achieved 
complete wound closure by week 12 of the Treatment Phase of the study will not be replaced.  
 
 
 
 
    
[Intentionally Blank]  
  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 36 of 59 
8 STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 STUDY PROCEDURE OVERVIEW 
The below list is an overview of procedures or information to document at each visit.  Where added, i nformation in 
parentheses relate to the procedures listed in Table 2: Schedule of Activities  at the beginning of the protocol .  The 
detail about these procedures is found in the following section.  
8.1.1  SCREENING VISIT 1 (- 2 WEEKS [14 DAYS] ± 3 DAYS)  
1. Conduct Informed Consent Process  (Informed Consent & HIPAA)  
2. Review Eligibility Criteria  (Inclusion/Exclusion)  
3. Collect Demographics & Medical History from Patient  
4. Perform Physical Examination  
5. Perform Vascular Perfusion Assessment  (if most recent ABI is greater than 3 months old  or no 
assessment is present in subject’s medical records ) 
a. ABI, Toe Pressure, or  TcPO 2 (ABI is preferred)  
6. Discuss Requirements for Study Compliance (Treatment Compliance Review)  
7. Perform Sharp Debridement on Study Ulcer, if needed (Debridement)  
8. Collect Images of the DFU (Photography)  
9. Perform Ulcer Assessments 
10. Treat Subject Using SOC  Procedures  (Standard of Care ) 
11. Train subject on wound cleansing and dressing changes  
12. Apply Boot , if applicable (Boot Application)  
13. Document Concomitant Medications  & Procedures (ConMeds and Other Procedures)  
8.1.2  SCREENING VISIT 2 (- 1 WEEKS [7 DAYS] ± 3  DAYS)  
1. Review Eligibility Criteria  (Inclusion/Exclusion)   
2. Review Study Compliance with the Subject  (Treatment Compliance Review)  
3. Perform Sharp Debridement on Study Ulcer, if needed (Debridement)  
4. Collect Images of the DFU (Photography)  
5. Perform Ulcer  Assessments 
6. Treat Subject Using SOC  Procedur es (Standard of Care)  
7. Apply Boot , if applicable  (Boot Application)  
8. Document Adverse Events  
9. Document Concomitant Medications & Procedures (ConMeds and Other Procedures)  
8.1.3  RANDOMIZATION VISIT ( DAY 0)  – POINT OF ENROLLMENT  
1. Review Eligibility Criteria  (Inclusion/Exclusion)   
2. Review Study Compliance with the Subject  (Treatment Compliance Review)  
3. Perform Sharp Debridement on Study Ulcer, if needed (Debridement)  
4. Collect Images of the DFU (Photography)  
5. Perform Ulcer  Assessments 
6. Randomize Subject  (Randomization)  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 37 of 59 
7. Treat per Randomization Group  (SOC + Treatment)  
a. AMNIOEXCEL Plus Cohort  (Discontinue Daily Dressing Regimen)  
b. Apligraf Cohort  (Discontinue Daily Dressing Regimen)  
c. Standard of Care Cohort  
8. Apply Boot , if applicable  
9. Train subject on maintenance of dressing and when to call/return to the study site  
10. Document Adverse Events  
11. Document Concomitant Medications & Procedures (ConMeds and Other Procedures)   
8.1.4  WEEK 1 (7 ± 3 DAYS) THROUGH WEEK 11 (77 ± 3 DAYS); UNSCHEDUL ED VISITS  
1. Review Study Compliance with  the Subject (Treatment Compliance Review)  
2. Collect MRU Data  for the Previous Week  (MRU Assessment)  
3. Perform Sharp Debridement on Study Ulcer, if needed (Debridement)  
4. Collect Images of the DFU (Photography)  
a. Important: If the subject has been randomized to the Apligraf cohort, the non -adherent layer should 
not be removed at the Week  1 timepoint (See section 6.1.2.3  RECOMMENDED INSTRUCTIONS FOR 
USE OF APLIGRAF ).  Sites do not need to image the wound at Week 1 if the subject is in the Apligraf 
cohort; however, if the non -adherent layer disengages from the wound of its own volition, imaging 
may occur.  In this latter case, care should be taken to not disturb the Apligraf.  
5. Perform Ulcer  Assessments 
6. Treat per Randomization Group ( SOC + Treatment)  
a. AMNIOEXCEL Plus Cohort  (Weekly Dressing Changes, Only)  
b. Apligraf Cohort  (Weekly Dressing Changes, Only)  
c. Standard of Care Cohort 
7. Apply Boot, if applicable  
8. Document Adverse Events 
9. Document Concomitant Medications & Procedures (ConMeds and Other Procedures)  
8.1.5  WEEK 12 (84 ± 3 DAYS ) 
1. Review Study Compliance with the Subject (Treatment Compliance Review)  
2. Collect MRU Data  for the Previous Week  (MRU Assessment)  
3. Collect Images of the DFU (Photography)  
4. Perform Ulcer  Assessments 
5. Apply Boot, if applicabl e 
6. Document Adverse Events  
7. Document Concomitant Medications & Procedures (ConMeds and Other Procedures)  
8.1.6  FOLLOW- UP VISIT S - WEEK S 13 & 14  (91 & 98  ± 3 DAYS) 
1. Collect MRU Data  for the Previous Week  (MRU Assessment)  
2. Collect Images of the DFU (Photography)  
3. Perform Ulcer  Assessments 
4. Apply Boot, if applicabl e 
5. Document Adverse Events  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 38 of 59 
6. Document Concomitant Medications & Procedures (ConMeds and Other Procedures)  
IMPORTANT:  If the subject’s wound is open at Follow -up visit 1 (e.g., week 13), the subject is exited from the study 
and is marked as having completed their study requirements.  The site will note why they believe the wound is still 
open.  
8.2 ASSESSMENTS  
 
The following assessments will occur for each subject consented into  the study  according to the Study 
Procedure Overview above : 
 
• Informed Consent (Screening Visit 1) – ALWAYS THE FIRST ACTIVITY  
Please see the section dedicated to the informed consent process in section 10.1.1 of this 
document . 
• Eligibility  (i.e., Inclusion/Exclusion; Screening Visits 1 and 2 and Randomization [Day 0])  
The Investigator will review medical records and query the subject as needed to determine if the subject meets the inclusion and exclusion criteria for the study.   Inclusion/exclusion review will 
be complete  on Randomization (Day 0) after the Investigator reviews the amount of wound 
closure  after debridement .  The site will enter whether the subject meets each applicable criterion 
into the ED C system.  
• Demographics & Medical History (Screening Visit 1)  
The site will collect the subject’s date of birth, gender, ethnicity, race, and will assess nicotine use.  Diabetic history will be noted.  Diabetes type, date of diagnosis, date of most recent HbA1c test, 
and %HbA1c will be documented.  A separate HbA1c test does not need to occur unless the subject’s most recent test is greater than 3 -months (90 days) from the date of Screening Visit 1.  
Documentation of other medical conditions will be made based on body systems (e.g., cardiovascular, dermatologic, endocrine, gastrointestinal, etc.).  
• Physical examination (Screening Visit 1)  
Height  and weight, along  with blood pressure , will be documented.  Sites will document any 
abnormalities in any of the following: extremities, neurologic, cardiovascular, musculoskeletal, dermatological and/or other systems.  A vascular perfusion assessment (either the ABI,  systolic 
pressure of the great toe, or TcPO
2) will be noted.  Sites will document whether or not the subject 
has multiple DFUs.  
• Vascular Perfusion Assessment (Screening Visit 1, if necessary)  
Perform one of the following:  
o ABI (Preferred Assessment) 
The ABI is the ratio of the brachial pressure (i.e. , blood pressure in the arm) to the 
blood pressure in the ankle.  Briefly, the blood pressure is obtained in the arm (brachial) and then obtained in a similar manner in the ankle.  To obtain the ratio (i.e., index ), divide the systolic pressure from the ankle b y that obtained in the 
arm.   
 
𝐴𝐴𝐴𝐴𝐴𝐴 =  𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆  𝑃𝑃𝑃𝑃𝑃𝑃𝑆𝑆𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆  𝑃𝑃𝑃𝑃𝑃𝑃𝑆𝑆𝑆𝑆𝑃𝑃𝑃𝑃𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 
 Subjects enrolled in this study must have an ABI of between  0.65 and 1.2.   NOTE: 
An ABI result obtained within 3 months of the first screening visit may be used to qualify the potential subject for participation in this study.   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 39 of 59 
 
o Toe Pressure  
The blood pressure within the toe is measured in much the same way as obtaining 
blood pressure in the arm.  Briefly, use a Doppler probe to determine  that a pulse 
is present at the base of the great toe.  Apply the correct sized cuff to the great toe and place the Doppler probe distal to the cuff (the pulse should be audible).  Inflate the cuff sufficiently to occlude the pulse and slowly release the c uff.  Note 
the pressure, in mmHg, when the pulse returns.  To participate in this study, the potential subject must have a toe pressure greater than 50mmHg in the foot with the study ulcer.  
o Transcutaneous Oxygen Level (TcPO
2) 
TcPO 2 is a measure of oxygen delivery to a local area.  A special machine must be 
used to assess TcPO 2.   Briefly, electrodes for the sensor will be placed onto the 
intact skin close to the study ulcer.  The oxygen sensor then can read the oxygen 
content of the tissue and reports this as mmHg pressure.  Each site should refer 
to the equipment’s manual for specific and correct instructions for use.  For this 
study, potential study candidates must have a TcPO 2 greater than 40 mmHg.  
 
• Treatment Compliance  Review  (Screening Visit 1 & 2, Randomization,  Weeks 1 - 12) 
Screening Visits 1 &2:  T he site will instruct the subject on how to perform  daily dressing changes 
and apply the offloading  boot , if offloading is used.   
 Randomization Visit: For subjects randomized to the SOC cohort, the s ite will instruct the subject 
on how to perform daily dressing changes and apply the offloading boot, if offloading is used.  For those subjects randomized to the AMNIOEXCEL Plus or Apligraf cohorts, only the offloading boot will be discussed, if applicable.  Subjects in these arms do not change their dressings at home.  
 On subsequent visits, the site will ask the subject whether they are performing  the dressing 
changes and /or offloading , as applicable .    To appropriately assess compliance, the site will ask 
the subject if they are wearing their boot at all times except when bathing or sleeping.  Further, when the offloading boot is removed, the site will examine the exterior of the boot for signs of wear and the interior for evidence of depressions in the boot liner.  The site will document their assessment of compliance on the appropriate eCRF.  Note: The site should replace worn liners as 
necessary.  
 
• Debridement (Screening Visit 1  & 2,  Randomization,  Weeks 1 - 11) 
Debridement is the removal of dead, damaged, or devitalized tissue to improve the healing potential of the remaining healthy tissue.  Removal may be sharp, mechanical, chemical, or autolytic (self-digestion) ; however, in this study only sharp debridement will be used . 
 Following debridement, hemostasis should be obtained with pressure.  The use of silver nitrate 
sticks, styptic pencils or electro -cautery should be avoided as these coagulation methods induce 
further tissue damage.  
 
•  Photography (All Study Visits)   
For this study, imaging software created by Tissue Analytics, Inc. will be used to collect images of 
the subjects’ ulcers.   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 40 of 59 
 
Using the app provided by Tissue Analytics, Inc., sites will take an image of the study ulcer.  These images will be used to: 1) document the status of the wound and 2) use planimetry to calculate the area of the open wound.  Photographs of the wound will be taken after the dressings are 
removed, the wound is cleansed, debrided, and hemostasis has been achieved, if debridement is 
performed.  The app will automatically measure the wound area; the site does not need to enter this information into the EDC syst em. 
 The site will use the imaging methodology set forth in the current imaging vendor’s procedure manual.  Imaging should be conducted in such a manner as to eliminate (to the best of the site’s ability) any identifying information such as tattoos, birthmarks, etc.  
 Important: If the subject has been randomized to the Apligraf cohort, the non -adherent layer 
should not be removed at Week 1 (See section 6.1.2 .3 RECOMMENDED INSTRUCTIONS FOR USE 
OF APLIGRAF ).  Sites do not need to image the wound at Week 1 if the subject is in the Apligraf 
cohort; however, if the non -adherent layer disengages from the wound of its own volition, 
imaging may occur.  In this latter case, care should be taken to not disturb the Apligraf.  
 
• Ulcer Assessments  
• Screening Visits 1 &2  
The location of the ulcer will be noted.  Extent of ulceration (i.e., tunneling, tendon exposure, etc.), exudate assessment, and infection assessment.  Ulcer area will always be assessed 
using the post -debridement (or pre -debridement if no debridement was performed) 
photographs.  
 
• All Study Visits following Screening Visits 1 & 2 Exudate assessment, infection assessment, and investigator assessment of wound closure will be collected.  
 
• Completion of Study Assessment (Follow Up Visits)  
Sites will assess completion status of the subject and will make a determination about the 
status of the wound (closed or not).  
 
• Standard of Care, Offloading (Screening Visits 1 & 2, Randomization, Weeks 1 -11 as applicable)  
Sites will apply SOC materials and boots according  to the procedures laid out in section 6.1.2 and 
will document in the EDC system what materials were used.   The site will document that a weekly 
kit was used and that they provided materials and training to the subject as applicable.  
 
• Randomization (Day 0)  
Sites will review eligibility criteria a final time and document that the subject has met these criteria 
in the EDC system.  The EDC system will provide the site with the appropriate cohort based on a pre-determined randomization scheme.  The site will pr oceed with applying the appropriate 
treatment products based on the mandated cohort for that subject.  
 
• Investigational Product, Offloading ( Randomization, Weeks 1 -11, as applicable)  
Sites will apply investigational product and SOC  materials and boots , if applicable,  according to 
the procedures laid out in section 6.1.2 and will document in the EDC system what materials were 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 41 of 59 
used.   Sites will document the product used (AMNIOEXCEL Plus or Apligraf), the product’s lot 
number, and method of securing.  The site will also document that a weekly kit was used, that 
they provided materials and training to the subject as applicable.  
 
• MRU Assessment  (Weeks 1 – 12, Follow -Up Weeks 1 & 2) 
As applicable, t he site will document  the following for the subject’s previous  visit week:  
o Any and all DRG Codes, using ICD -10, that were  or would be  applied to the subject   
o The associated CPT codes and modifiers  for those CPT codes  
 
• Concomitant Medications (All Study Visits)  
Sites will query the subjects at each visit about any medications they are currently taking.  Only 
medications that (1) affect the wound area, (2)  affect the  limb, (3) are related to the treatment of 
the wound, (4) are being used to treat any AEs that develop during this study, will be documented.  The name, indication/reason for use, dose, route, frequency, start/stop date, and whether the medication is being used to treat any adverse events will be noted.  
 
• Assessment of A dverse Events  (All Study Visits after Screening Visit 1)  
After the initial screening visit, sites will report full information on those  AEs possibly, probably, 
or definitely -related to the investigational product or study procedure.   Other AEs that are not 
related or unlikely related will only have basic information collected (Stop and Start Date) .  If these 
AEs change in relationship (e.g., an ongoing unrelated AE becomes possibly related) ful l 
information will be collected.  
 Sites will collect the AE onset date and a description of the event.  The sites will then make a determination as to whether the AE is Serious or not and will grade its severity marking it as either (1) mild, (2) moderate, or (3) severe.   For any treatment or procedure -related SAEs that are graded 
as (1) possibly, (2) probably or (3) definitely -related, t he site will also indicate whether the event 
is anticipated or unanticipated.  Definitions of the se terms can be found in the following section 
of the protocol.  
 
Sites will also note the action taken (none, medication given, hospitalization required, surgical 
intervention, or other), and the outcome of the AE (resolved with or without sequelae, death, ongoing, or other) .  If available , an adverse event resolution date will be noted.  The site will also 
make a determination as to whether the AE caused the subject to discontinue participation in the study.  
 See Section 8.3 below for more information on AE definitions and procedures.  
 8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERS E EVENT (AE)  
 
For the purposes of this research protocol, an a dverse event  means any untoward medical 
occurrence or adverse reaction (AR) associated with the use of an intervention in humans, that is 
considered possibly, probably, or definitely -related to the investigational product  or study 
procedure .  All events starting or worsening after the first randomized treatment through study 
exit will also be collected.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 42 of 59 
 
8.3.2  DEFINITION OF INVESTIGATIONAL PRODUCT  
 
Investigational Product is defined as either the AMNIOEXCEL Plus or Apligraf allograft.   
 
8.3.3  DEFINITION OF STUDY PROCEDURE  
 Study Procedure is defined as the application of any of the SOC  products used in the care of the 
wound and/or sharp  debridement.  
 
8.3.4  DEFINITION OF ADVERS E REACTION  
 An Adverse Reaction is defined by the FDA as any noxious or unintended response for which there is a reasonable possibility that the HCT/P caused the reaction.  This includes, but is not limited to, 
the transmission of communicable diseases or infectious agents such as viruses, bacteria, or fungi, 
or allergic reaction. In addition to your normal adverse event reporting procedures in this study, adverse reactions should be reported within 2 business days to a Sponsor representative.  This 
person can either be the Clinical Research Manager, the Clinical Research Associate assigned to the site, or the Medical Monitor.  In this study, only those subjects randomized to receive 
AMNIOEXCEL Plus may experience an adverse reaction as it is the only HCT/P used in this  study.  
 8.3.5  DEFINITION OF SERIOU S ADVERSE EVENT (SAE)  
 
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it 
results in any of the following outcomes:  
o Death,  
o a life -threatening adverse event,  
o inpatient hospitalization or prolongation of existing hospitalization,  
o a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or  
o a congenital anomaly/birth defect.  
8.3.5.1  SUB -DEFINITIONS OF SERIOUS ADVERSE EVENT  COMPONENTS   
 
• Death - If it is suspected that the death was an outcome of the adverse event  
• Life-threatening  - If it is suspected that the subject was at substantial risk of dying at the time of 
the adverse event, or use / continued use of the  investigational (study) device or study procedure 
might have resulted in the death of the subject.  
• Hospitalization (initial or prolonged)  - If subject admission to the hospital or prolongation of 
hospitalization was a result of the adverse event.  Emergen cy room visits that do not result in 
admission to the hospital should be evaluated for one of the other serious outcomes (e.g., life -
threatening; required intervention to prevent permanent impairment or damage; other serious 
medically important event).  
• Disability or Permanent Damage  - If the adverse event resulted in a substantial disruption of a 
person's ability to conduct normal life functions, i.e., the adverse event resulted in a significant, 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 43 of 59 
persistent or permanent change, impairment, damage or disruption in the subject’s body 
function/structure, physical activities and/or quality of life.  
• Congenital Anomaly/Birth Defect  - If it is suspected that exposure to the investigational (study) 
device or study procedure prior to conception or during pregnancy ma y have resulted in an 
adverse outcome in the child.  
• Required Intervention to Prevent Permanent Impairment or Damage  - If it is suspected that 
medical or surgical intervention was necessary to preclude permanent impairment of a body function, or prevent permanent damage to a body structure, either situation suspected to be due to the
 use of the study intervention or stu dy procedure  
• Other Serious Important Medical Events  - When the event does not fit the other outcomes, but 
the event may jeopardize the subject and may require medical or surgical intervention 
(treatment) to prevent one of the other outcomes. Examples inclu de allergic bronchospasm (a 
serious problem with breathing) requiring treatment in an emergency room, serious blood 
dyscrasias (blood disorders) or seizures/convulsions that do not result in hospitalization. The development of drug dependence or drug abuse  would also be examples of important medical 
events.  
 Note: Planned hospitalization for a pre -existing condition, or a procedure required by the clinical 
study protocol, without serious deterioration in health, is not considered a serious adverse event.  
 
8.3.6  CLASSIFICATION OF AN ADVERSE EVENT  
8.3.6.1  SEVERITY OF EVENT  
 
For adverse events ( AEs) not included in the protocol defined grading system, the following 
guidelines will be used to describe severity.  
 
• Mild – Transient or mild discomfort; no limitation in activity;  no medical intervention or 
therapy required.  The subject may be aware of the sign or symptom, but tolerates it reasonably well.  
• Moderate – A moderate limitation in activity, minimal medical intervention and/or therapy 
is required to provide relief and/o r resolution . 
• Severe – A marked limitation in activity; advanced medical intervention and/or therapy, 
possibly including hospitalization was required to provide relief and/or resolution.  
 
8.3.6.2  RELATIONSHIP TO STUD Y INTERVENTION  
 
Relationship of all AEs to the investigational product, the comparator, or study procedure may be classified according to the following classifications/definitions.  
 • Not Related : The AE is due to an underlying or concurrent illness or the effect of another device, 
another drug or another  intervention and is not related to the study device and/or study 
procedure ( i.e. clearly  not related).  
• Unlikely: The relationship with the use of the investigational product or procedures  seems not 
relevant and/or the event can be reasonably explained by another cause, but additional information may be obtained.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 44 of 59 
• Possibly Related : The AE occurred in a reasonable time period relative to use  of the 
investigational product  and/or study procedure, which makes a causal relationship possible, but 
an alternative etiology is equally or less likely compared to the potential relationship to the 
investigational product  and/or study procedure ( i.e., may  be related).  
• Probably Related: The AE occurred in a reasonable time period relative to use  of the 
investigational product  and/or study procedure, and another etiology is unlikely or significantly 
less likely, which makes a causal relationship probable (i.e. likely  related).  
• Related : The AE occurred in a r easonable time period relative to use of the investigational product  
and/or study procedure and has a known relationship to the study device and/or study procedure, or is the only etiology available, making the causal relationship certain (i.e., clearly  related).  
 
8.3.6.3  EXPECTEDNESS  
 
Study Investigators  will be responsible for determining whether a product or procedure -related 
SAE is “anticipated”  or “unanticipated” .  A product or procedure -related S AE will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study intervention . 
 In determining expectedness of a S AE, the Investigator should consult the foll owing:  
• Previous experience with the product or procedure  
• Literature provided with any treatments (AMNIOEXCEL Plus; Apligraf product inserts)  
Although every adverse event occurring in an individual may be considered unanticipated, for 
the purposes of this study, anticipated events are those which are known to commonly occur in 
individuals with diabetes and DFUs.   Although every adverse event occurring in an individual 
may be considered unanticipated, for the purposes of this study, anticipated events are th ose 
which are known to commonly occur in individuals with diabetes and DFU s.   Those events 
include but are not limited to:  
• Ulcer enlargement, tunneling and/or undermining  
• Malodor  
• Erythema  
• Edema  
• Maceration  
• Excessive drainage  
• Development of a new ulcer,  
• Ulcer infection or abscess,  
• Osteomyelitis  
• Trauma/falls and /or 
• Amputation  
Although these remain adverse events, they are considered “anticipated”.  The following 
diagram (Figure 3) is to assist in the expectedness determination:  
 
[See Next Page for Diagram]  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 45 of 59 
 
8.3.7  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE) may come to the attention 
of study personnel during study visits and interviews of a study subject  presenting for medical 
care, or upon review by a study monitor.   All AEs will be captured on the appropriate  eCRF as 
noted above in section 8.2 .  
 
Any medic al condition that is present at the time that the subject  is initially screened will be 
considered as pre-existing and not reported as an AE. However, if the study subject ’s condition 
deteriorates at any time during the study, it will be recorded as an AE.   
 Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each episode.  
 The study Investigator  will record all reportable events with start dates occurring any time after 
informed consent is obtained the last day of study participation  (i.e., Follow -Up Visit 2) .  At each 
study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit.  Events 
will be followed for outcome information until resolution or stabilization.  
 If an AE is not resolved by the end of the study, that event will be marked as such by the Investigator.  
 
Is the  
nature, severity, or 
frequency of the SAE 
consistent with the risk 
information previously 
described for the 
product or procedure ? 
Yes 
Is the AE Serious?  
Is the SAE  
Product Related ? 
Yes 
Expectedness 
is Not 
Applicable  
Is the SAE  
Procedure Related ? 
No 
No 
No 
Yes 
This SAE is  
ANTICIPATED  
Report to 
EDC 
Yes 
This SAE is UNANTICIPATED  
REPORT TO THE SPONSOR WITHIN 10 
BUSINESS DAYS via the EDC system.  
Check and Follow IRB Reporting 
Requirements.  
No 
Figure 3: Expectedness Determination of Investigational Product or Procedure -Related SAEs  
Start  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 46 of 59 
8.3.8  ADVERSE EVENT REPORT ING  
 
Adverse events will be reported to the Sponsor using the eCRFs in the EDC  as the Investigator 
becomes aware of them.  The Investigator is responsible for reporting any and all adverse events 
to their federal, state, and local oversight committees (e.g., IRBs) as required by that committee.  
 
Adverse reactions to the AMNIOEXCEL Plus must  be reported within  2 business days to the 
Sponsor (Integra)  via the AE eCRF in the EDC system .  Important note: Subject records must be 
maintained for the purpose of tracing tissue post -transplant per The Joint Commission on 
Accreditation of Healthcare Organizations and FDA requirements.  The AMNIOEXCEL Plus  ID 
number must be recorded in the recipient’s medical record.  Patient labels which include tissue numbers are contained in the AMNIOEXCEL Plus  package to aid in the tracking process.  
 8.3.9  SERIOUS ADVERSE EVENT REPORTING  
 
Investigators are instructed to report SAEs to Integra within 10 business day s of the Investigator 
becoming aware of the SAE.  
 SAEs must be reported by the Investigator to Integra by completing the SAE eCRF. All SAEs and 
deaths that are possibly related, probably related, or definitely related to the investigational 
product or study procedures must be reported . The information collected will include a minimum 
of the following: subject number, a narrative description of the event, lot number of device used on subject, and an assessment by the Investigator as to the intensity of the event and relatedness to study device. Follow -up information on the SAE may be requested by the Sponsor.  
 Any subjects reporting SAE s that have not resolved by their last treatment visit will be followed 
via phone or clinic visit through resolution or 14 days post final visit, whichever comes first.  
  
8.3.10 UNANTICIPATED SERIOU S ADVERSE EVENT REPORTING  
 
Investigators are instructed to report UNANTICIPATED SADEs to Integra AND  to the IRB , if 
required, within 10 business days of the Investigator becoming aware of the SAE.  NOTE: Local 
IRBs may require different timelines and/or reporting requirements.  Each Investigator approved 
to conduct research under the authority of a local IRB is responsible for knowing these 
requirements and for abiding by them.  
 
 
9 STATISTICAL CONSIDER ATIONS   
 
This section presents general information about statistical methodologies and concepts for this study.  
Further technical details ( e.g.,  statistical analysis methods and data conventions) will be provided in the 
Statistical Analysis Plan (SAP).  
9.1 STATISTICAL ENDPOINTS  
 
• Primary Efficacy Endpoint(s):  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 47 of 59 
 
The primary endpoint of this study is the incidence of complete wound closure, as assessed by 
the Investigator at or before Week 12 of the Treatment Phase and confirmed closed 2 weeks later .  
Confirmed complete wound closure is defined as complete skin re -epithelialization that is without 
drainage or dressing requirements two weeks later.  
 A subject is considered to have a closed wound (i.e., a closure success) if the subject’s treated 
wound closes between week 1 and 12 and is noted as closed on both follow -up visits.  
 A subject is considered to not have a closed wound (i.e., a closure failure ) if they meet any of the 
following:  
 the subject’s treated wound does not close by week 12  
 the subject’s treated wound closes between week 1 and 12 and is noted as open on either or both of the follow -up visits.  
 A subject is considered to have an undetermined wound closure if the subject’s treated wound closes between week 1 and 12 and the subject misses either or both of the follow -up visits.  These 
subjects may become part of extended analyses.  
 
• Secondary Efficacy Endpoint(s):  
 
1. Proportion of subjects with complete closure of the study ulcer at or before Week 12 as assessed by computerized planimetry.  
2. Proportion of subjects with complete wound closure of the study ulcer at or before Week 12 as assessed by independent, blinded, as sessment of photographs.  
3. Time to complete wound closure, as assessed by the Investigator.  
4. Time to complete wound closure, as assessed by computerized planimetry.  
5. Rate of wound closure, as assessed by computerized planimetry.  
6. Medical resource utilization associated with treatment of DFU and related complications as determined by a comparison of estimated costs from the presumed billing codes which would have been used for each patient.  
 9.2 SAMPLE SIZE  DETERMINATION  
 A total of 114 subjects, 38 per cohort, will be enrolled, inclusive of a 20% in -study attrition rate.   
 
It is assumed that the maximum wound closure rate is 90% with no difference between the study cohorts.  
Based on the 38 subject per cohort sample size, the half width of the 95% confidence interva l for the 
wound closure rate is 13.5%.   However, the study is not adequate for hypothesis testing .      
 
9.3 POPULATIONS FOR A NALYSES  
 The following population s are defined for the analysis of the data to be collected as part of this 
study.  All decisions on eligibility for inclusion in these populations will be made prior to the end of the study.   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 48 of 59 
 
The Intent- to-Treat (ITT) population, defined as all randomized subjects  who received at least one 
application of study intervention , will be the primary population for the analysis of primary and 
secondary efficacy endpoints.     
 The Per Protocol (PP) population, defined as all subjects in the ITT population for who  there were 
no major protocol violation, will be used in supportive as the primary analysis dataset analyses of 
the primary and secondary endpoints. In efficacy or exploratory analyses, covariate analyses will be 
conducted to assess the impact of various prognostic factors on closure and also to demonstrate the robustness of the primary analysis.  Prognostic factors (i.e., covariates) will be included if they are found to be con tributing factors (i.e., the individual covariate p -value is less than 0.10).  Potential 
prognostic factors to be considered include:  
• Ulcer area   • Duration of ulcer  
• Gender    • HbA1c  
•Ulcer Location    • Diabetes type  
• Race    • Nicotine Use  
• Baselin e BMI   
 
9.4 STATISTICAL ANALYSES  
 9.4.1  GENERAL APPROACH  
All study data collected in the eCRF will be presented in subject data listings. Statistical analyses will be 
performed using SAS
® for Windows, version 9.4 or later. Descriptive statistics (n, mean, standard 
deviation, median, minimum and maximum) will be calculated by treatment group for continuous 
variables.  Frequencies and percentages will be presented by treatment group for categorical variables.  
Unless otherwise specified, all testing will be performed using two -sided test at the 0.05 level of 
significance.   
9.4.2  SUBJECT DISPOSITION  
The disposition of all subjects who sign an ICF will be provided. The numbers of subjects screened, 
randomized, completed, and discontinued during the study, as well as the reasons for all post -
randomization discontinuations will be summarized by treatment  group, for all sites  combined 
and each site separately. Disposition and reason for study discontinuation will also be provided 
as a by -subject listing.   
9.4.3  PROTOCOL DEVIATION S 
Protocol deviations will be identified and listed by study sites  based on the def initions and 
constraints set forth in section 10.1.9 of the protocol, below . 
9.4.4  BASELINE DESCRIPTIVE  STATISTICS  
 
Demographic data including but not limited to age, race, gender and ethnicity and other baseline 
characteristics, but not limited to medical and surgical history will be tabulated by treatment and 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 49 of 59 
overall. Summarized demographic data will include mean, standard deviation, minimum and 
maximum; as well as analogous summary statistics for presenting diagnosis and other relevant patient characteristic factors.  
 
9.4.5  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
 
The primary objective of this study is to assess the p roportion of subjects who achieve complete 
wound closure by 12 weeks  and confirmed 2 weeks later, for the Active Treatment Groups 
(AMNIOEXCEL Plus Placental Allograft Membrane with SOC , Apligraf bi-layered skin substitute 
with SOC) and Control Treatment Group (or SOC  alone).    
 The primary analysis will be conducted on the ITT population.  The proportion of subjects with confirmed closed study wound, as assessed by the investigator, will be compared between AMNIOEXCEL Plus and Apli graf, and  AMNIOEXCEL Plus  and SOC.  The proportion of subjects with 
confirmed complete wound closure will be compared using the Cochran– Mantel –Haenszel (CMH) 
test.  
 For the primary efficacy analysis, missing values will be imputed using last observation carried forward (LOCF).  The difference s in confirmed complete wound closure rate between treatment 
arms will be summarized along with 95% confidence intervals.  
 
9.4.6  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
 The following are for exploratory analysis purposes.  
 Proportion of ulcers with complete wound closure during the treatment phase as assessed by planimetry will be compared using Logistic Regression with selected baseline covariates  in the 
model.   
 Time to complete wound closure will be analyzed using log rank test or Cox proportional regression model.  Kaplan -Meier methods will be used to present median time to complete 
wound closure.    Summary statistics will be provided for the rate of wound closure for the two treatment groups.   
 
 9.4.7  SAFETY ANALYSES  
AEs/SAEs related to the investigational product , study ulcer and/or study procedures and will be 
recorded.  
AEs will be coded according to the most recent version of the Medical Dictionary for Regulatory 
Activities (MedDRA) AE coding dictionary, and grouped by body system.  The number and 
percentage of subjects experiencing at least one AE of any type, AEs within each body system and 
AEs within each preferred term will be presented for each treatment group.  Separate summaries 
will be provided for all AEs, device related AEs, SAEs and AEs leading to withdrawal.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 50 of 59 
All safety parameters will be summarized descriptively by treatment assignment.  No inferential 
statistics are planned.  
Listings of complications will be presented, include  complication type, relation to s tudy device, 
relation to procedure, action taken, and clinical outcome. Separate listings will be constructed for 
complications with possible, probable, or definite relationship to the device, serious complications, and for all complications. The listing for all complications will be sorted by complication type.  
 9.4.8  PLANNED INTERIM ANAL YSES  
 
An interim analysis will occur after 50% of subjects have satisfied  the primary endpoint of the 
study.   Descriptive statistics will be provided.  Primary and secondary endpoints will be evaluated 
at the time of interim analysis.   
 9.4.9  SUB -GROUP ANALYSES  
Sub-group analysis is not planned for this study.   
9.4.10 TABULATION OF INDIVI DUAL SUBJECT DATA  
 
All collected study data will be presented in subject data listings.  Details will be provided in SAP.
 
 9.4.11 MULTIPLICITY ADJUSTMENT  
There will be no multiplicity adjustment for primary and secondary endpoint analysis for 
comparing three treatment groups  nor any adjustment for the planned interim analysis . 
9.4.12 EXPLORATORY ANALYSES  
 
Exploratory analyses will be performed to examine wound closure status at Week 4 of Treatment and wound closure status at the 2 -week follow -up visit  
Proportion of subjects with confirmed complete wound closure of the study ulcer at week  4 
Treatment Phase, and at the 2 -week follow -up visit as assessed by computerized planimetry  for 
each of the treatment groups will be summarized.  A point estimate will be presented along with 
the exact 95% confidence interval based on the binomial distribution . 
   
[Intentionally Blank]  
   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 51 of 59 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL  CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
 10.1.1 INFORMED CONSENT PROCESS  
 10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED TO SUBJECT S 
 
Consent forms describing in detail the study intervention, study procedures, and risks will be 
given to the subject  and written documentation of informed consent  (i.e., a signed consent 
form)  is required prior to performing any study -related procedures .    
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. The subject must agree to participate in the study and sign the informed consent document prior to any procedures being done specifically for the study .  Consent forms will be IRB -approved and the subject  will 
be asked to read and review the document.   A verbal explanation will be provided in terms 
suited to the subject ’s comprehension of the purposes, procedures, and potential risks of the 
study and of their rights as research subject s.  Subject s will have the opportunity to carefully 
review the written consent form, ask  questions and discuss the study with their 
family/friends/surrogates prior to agreeing to participate. Subject s must be informed that 
participation is voluntary and that they may withdraw from the study at any time, without prejudice.  A copy of the signed informed consent document will be given to the subject s for 
their records. The informed consent process will be  documented in the subject’s medical record 
and source document, the  rights and welfare of the subject s will be protected by emphasizing 
to them that the quality of their medical care will not be adversely affected if they declin e to 
participate in this study.  
10.1.2 STUDY DISCONTINUATIO N AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause.  Written notification, documenting the study s uspension or termination, will 
be provided by the suspending or terminating party to investigator  and oversight authorities (e.g., 
IRB).  If the study is prematurely terminated or suspended by the Sponsor , the  Investigators will 
promptly inform study subje cts, the IRB .  If an oversight authority (e.g., IRB) suspends or 
terminates a study at a site, the Investigator should notify the Sponsor within 24 hours.  S tudy 
subject s will be contacted, as applicable, and be informed of changes to their visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subject s 
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to prot ocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 52 of 59 
 
The study may resume if resolution of the suspending/terminating factor occurs.  
 
10.1.3 CONFIDENTIALITY AND P RIVACY  
 
Subject  confidentiality and privacy is strictly held in trust by the participating I nvestigators, their 
staff, oversight authorities (e.g., IRBs), the Sponsor , and third party affiliates . This confidentiality 
is extended to cover all data collected within the confines of this protocol . Therefore, the study 
protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the Sponsor.  
 All research activities will be conducted in as private a setting as possible.  
 
The study monitor, other authorized representatives of the sponsor, representatives of the IRB , 
regulatory agencies  or pharmaceutical company supplying study product may inspect all 
documents and records required to be maintained by the investigator, including but not limited 
to, medical records (office, clinic, or hospital) and pharmacy records for the subject s in this study. 
The clinical study site will permit access to such records.  
 The study subject ’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location 
for as long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.  
 Study subject  research data, which is for purposes of statistical analysis and scientific reporting, 
will be transmitted to the spons or via an EDC system (Clindex®, Fortress Medical Systems) . This 
will not include the subject ’s contact or identifying information. Rather, individual subject s and 
their research data will be identified by a unique study identification number. The study dat a entry 
and study management systems used by clinical sites and by the Sponsor’s  research staff will be 
secured and password protected. At the end of the study, all study databases will be de -identified 
and archived at the Sponsor’s headquarters . 
 10.1.4 FUTURE USE OF DATA  
 
Data collected for this study will be analyzed and stored at the Sponsor’s headquarters . After the 
study is completed, the de -identified, archived data will be retained by the Sponsor and will not 
be used by other researchers outside of the study.   Deidentified images obtained in the course 
of study conduct, will also be stored with other study data.  All stored data may  be used as part 
of future post -hoc analyses by the Sponsor.  
 
10.1.5 SAFETY OVERSIGHT  
 
Safety oversight will be under the direction of the Medical Monitor.  The Medical Monitor will 
review SAEs related to the study and provide guidance on actions, if any, which need to be taken by the study team.  
 
 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 53 of 59 
10.1.6 CLINICAL MONITORING  
 
Monitoring of the clinical data collected for a study  is performed  to ensure that the rights and 
well- being of trial subject s are protected, that the reported trial data are accurate, complete, and 
verifiable, and that the conduct of the trial is in compliance with the currently approved 
protocol/amendment(s), with ICH GCP, and with applicable regulatory requirement(s).  
 
• Monitoring for this study will be performed by the Sponsor  or authorized Sponsor 
representative.  
• Monitoring will incorporate risk -based  (e.g., centralized ) and on -site review of data.  The 
frequency of monitoring visits will vary based on factors such as information seen during risk -
based monitoring activities, frequency of enrollment, and other pertinent constraints ( i.e., 
audit preparation, etc.).  The extent of the monitoring will be to achieve  comprehensive , 
100% source data verification . 
• The schedule of monitoring activities (i.e., timing of confirmation letters, reports, follow up letters, etc.) will follow the Sponsor’s SOPs and the Clinical Monitoring Plan (CMP).  
 10.1.7 QUALITY ASSURANCE AND QUALITY CONTROL  
 
Following written Standard Operating Procedures ( SOPs ), the monitors will verify that the clinical 
trial is conducted and data are generated  and biological specimens are collected , documented 
(recorded), and reported in compliance with the protocol, ICH GCP, and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by lo cal 
and regulatory authorities.  
 
10.1.8 DATA  HANDLING  AND RECORD  KEEPING   
 10.1.8.1  DATA COLLECTION AND  MANAGEMENT RESPONSI BILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site I nvestigator. The I nvestigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.   
 Hardcopies of the study visit worksheets  may  be provided for use as source document  
worksheets for recording data for each subject  enrolled in the study.  Data recorded in the eCRF 
derived from any source documents should be consistent with the data recorded on th ose 
source documents .  
 
Clinical data (including AEs ), concomitant medications, and expected adverse reactions data , 
and randomization ) and clinical laboratory data will be entered into Clindex® (Fortress Medical 
Systems, Inc.) , a 21 CFR Part 11 -compliant data capture system provided by the Sponsor . The 
data system includes password protection and internal quality checks, such as automati c range 
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 54 of 59 
checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be 
entered directly from the source documents.  
 A randomization code will be developed by the Sponsor’s Statistical and Data Management 
teams and will be entered into the EDC mentioned above.  Only these teams will know or have 
access to these codes and/or the software systems used by the study’s investigators.  Randomization via the EDC system will only occur on Day 0 of the study after a subject meets all of the inclusion and exclusion criteria set forth in this protocol.  
 
10.1.8.2  STUDY RECORDS RETENT ION  
 
Study documents should be retained until at least 2 years after the formal closure of the clinical 
trial at the study site . These documents should be retained for a longer period, however, if 
required by local regulations. No records will be destroyed without the written consent of the 
sponsor, if applicable. It is the responsibility of the S ponsor to inform the investigator when 
these documents  no longer need to be retained.  If the documents are to be moved from the 
original Investigator’s site (i.e., for storage purposes), a formal letter must be sent to the 
Sponsor informing them of the move date, the new location, and, if  there is a change in 
oversight of the documents, the person who will be retaining oversight.  Letters can be sent to the Director of Global Clinical Operations at Integra LifeSciences.   The Sponsor should be 
contacted for the current and appropriate addre ss. 
 
10.1.9 PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, ICH GCP , or any 
supplementary protocols provided by third party vendors which have bearing on the collection of clinical trial data.  
 Major protocol dev iations are a subset of protocol deviations that might significantly affect the 
completeness, accuracy, and/or reliability of the study data or that might significantly affect a subject's rights, safety, or well- being.   
 The noncompliance may be either on the part of the subject , the I nvestigator, or the study site 
staff. As a result of major deviations, corrective actions are to be developed by the site and 
implemented promptly.  
 These practices are consistent with ICH GCP :  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance , sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site Investigator to use continuous vigilance to identify and report 
deviations  within 10 working days of identification of the protocol deviation, or within 5 
working days of the scheduled protocol -required activity.  All deviations must be addressed in 
study source documents, reported to the Sponsor .  Protocol deviations must be se nt to the 
reviewing IRB per their policies . The site I nvestigator is responsible for knowing and adhering 
to the reviewing IRB requirements.  Protocol deviations and their impact on the data analysis 
will be addressed in the study’s statistical analysis plan  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 55 of 59 
10.1.10  PUBLICATION AND DATA SHARING POLICY  
 
The results of the study may be published in scientific literature and may also be used in 
submissions to regulatory authorities. It is the intent of the Sponsor to publish or present the study results together with study results from the other sites, unless specific  written  
permission is obtained in advance from the Sponsor to publish separate results. The Investigator will ensure that any site and/or Sponsor personnel making a significant contribution to the study o r development of a manuscript are recognized as co -authors in any 
publication according to guidelines set forth by the International Committee of Medical Journal Editors (ICJME) . 
All information received by the Investigator concerning the Sponsor’s busines s operations 
(such as patent applications, product design, formulae, manufacturing processes, basic scientific data, or characterization or formulation information supplied to the Investigator and not previously published) is considered confidential by the  Sponsor and shall remain the sole 
property of the Sponsor. The Investigator agrees not to use it for any purpose other than conduct of the study without the prior written consent of Sponsor.  
It is understood by the Investigator that the Sponsor will use the information developed in this clinical trial (“Study Data”) in connection with the development of the AMNIOEXCEL Plus Placental Membrane. Therefore, Study Data may be disclosed to other Investigators or appropriate regulatory authorities. By agreeing to  participate in this clinical trial, the 
Investigator understands that he/she has an obligation to provide the Sponsor with complete and accurate Study Data.  
Publication and Disclosure: Because this is a multi- center trial, Investigators and/or their 
acad emic Institutions shall not independently publish, publicly disclose, present or discuss any 
Study Data or other information pertaining to their respective activities conducted under this study protocol until a multi -center publication is released under Sponsor’s direction, unless 
otherwise agreed upon in the study agreement.  
10.1.11  CONFLICT OF  INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence is critical.  Therefore , 
any actual conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial should  be disclosed and managed. Furthermore, persons 
who have a perceived conflict of interest should  have such conflict s managed in a way that is 
appropriate to their participation in the des ign and conduct of this t rial.   
 
10.1.12  FINANCING AND INSURA NCE  
This study is being financed by the Sponsor, Integra LifeSciences, Inc.  The Sponsor holds a 
certificate of insurance for this study.  
 
   
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 56 of 59 
10.2 ABBREVIATIONS AND DEFINITIONS  
Table 4: Abbreviations/Definitions  
Abbreviation/Term  Clarification/Definition  
ABI Ankle -Brachial Index  
AE Adverse Event  
AMNIOEXCEL Plus  AMNIOEXCEL® Plus Placental Allograft Membrane; the investigational product  
Apligraf  a living, bi -layered skin substitute; the comparator investigational product  
AR Adverse Reaction  
CFR Code of Federal Regulations  
CMH  Cochran –Mantel –Haenszel  
CMP  Clinical Monitoring Plan  
CONSORT  Consolidated Standards of Reporting Trials  
DAMA  Dehydrated Amniotic Membrane Allograft  
DFU(s)  Diabetic foot ulcer(s)  
dHACM  dehydrated Human Amnion/Chorion Membrane  
eCRF  Electronic Case Report Forms  
EDC Electronic Data Capture  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Glycosylated Hemoglobin (A.K.A., Hemoglobin A1C)  
HCT/P  Human Cellular and Tissue Based Products  
HIPAA  Health Insurance Portability and Accountability Act  
ICH International Conference on Harmonisation  
ICMJE  International Committee of Medical Journal Editors  
IRB Institutional Review Board  
ITT Intention -To-Treat  
LOCF  Last Observation Carried Forward  
LTFU  Lost-to-Follow -Up 
PP Per-Protocol  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SOC Standard of Care  
SOP Standard Operating Procedure  
T-AEPDFU -001 Protocol Number  
T-PAM  Tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T -PAM)  
TcPO 2 Transcutaneous Oxygen Level  
US United States  
 
 
 
[Intentionally Blank]  
  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 57 of 59 
 
10.3 PROTOCOL  AMENDMENT  HISTORY  
Table 5: Protocol Amendment History  
Version  Date  Description of Change s Brief Rationale  
1.0 14 Feb 2018  N/A, Original Version  N/A, Original Version  
2.0 01 Aug 2018  1. Removing Medical Monitor 
Information  
2. Table 2 and Sections 8.1.4 and 8.2 were modified to allow for no imaging in the Apligraf cohort at Week 1.  
3. Added numbering to sections in 6.1.2.  1. Change in staffing; if sites require 
medical assistance, they will be provided with current appropriate staff member’s information.  
2. Per the manufacturer’s instructions, the non -adherent 
layer should not be removed to allow for full integration of the product into the surface of the 
wound.  See Section 6.1.2 
Utilization and Administration, 
point 5 of the Apligraf Instructions for Use.  
3. To assist with and clarify edits 
above.  
3.0 05 Nov 2018  1. Modified language in Study 
Design the Summary section  
2. Added the following language to section 7.2: “If the subject’s wound is open at follow -up week 
1, the subject will be exited.  
They will be noted as having 
completed their study requirements.”  
3. The following language was added to section 8.1.6: “
IMPORTANT:  If the subject’s 
wound is open at Follow -up visit 1 
(e.g., week 13), the subject is exited 
from the study and is marked as having completed their study requirements.  The site will note 
why they believe the wound is still 
open .”
 
4. Figure 1 and Ta ble 2 have been 
updated  1. To clarify and be in line with the 
other changes in this document.  
2. To clarify what should happen to 
subject’s whose wounds re -open 
at follow -up visit 1.  
3. To clarify what should happen to 
subject’s whose wounds re -open 
at follow -up vi sit 1.  
4. These changes were made to be in 
line with the changes previously mentioned.  
 
 
  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 58 of 59 
11 REFERENCES  
 
1.  Snyder R, Shimozaki K, Tallis A, et al. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer. Wounds . 2016;28(3):70 -77. 
doi:10.1016/j.biortech.2005.10.045.  
2.  Bianchi C, Cazzell S, Vayser D, et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers. Int W ound J . 2017:1- 9. doi:10.1111/iwj.12843.  
3.  Martinson M, Martinson N. A comparative analysis of skin substitutes used in the management of diabetic foot ulcers. J Wound Care . 2016;25(Supplement 10):S8 -S17.  
4.  Organogenesis. Apligraf® Website. http://www. apligraf.com/professional/what_is_apligraf/index.html. Published 2010. Accessed 
January 1, 2017.  
5.  Singh N, Armstrong D, Lipsky B. Preventing Foot Ulcers in Patients with Diabetes. J Am Med Assoc . 2005;293(2):217 -228.  
6.  Snyder R, Cardinal M, Dauphinée D, Stavosky J. A Post- hoc Analysis of Reduction in Diabetic Foot 
Ulcer Size at 4 Weeks as a Predictor of Healing by 12 Weeks. Ostomy Wound Manag. 2010;56(3):44 -50. 
7.  Ramsey S, Newton K, Blough D, et al. Incidence, outcomes and cost of foot ulcers in pati ents with 
diabetes. Diabetes Care . 1999;22:382 -387.  
8.  Morbach S, Furchert H, Gröblinghoff U, et al. Long -Term Prognosis of Diabetic Foot Patients and 
Their Limbs: Amputation and death over the course of a decade. Diabetes Care . 2012;35(1):2021 -
2027.  
9.  Goodridge D, Trepman E, Sloan J, et al. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot Ankle Int . 2006;27(4):274 -280.  
10.  Frykberg R. Diabetic foot ulcers: current concepts. J Foot Ankle Surg. 1998;37:440-446.  
11.  Waycaster  C, Carter MJ, Gilligan AM, Mearns ES, Fife CE, Milne CT. Comparative cost and clinical 
effectiveness of clostridial collagenase ointment for chronic dermal ulcers. J Comp Eff Res . 
2017:cer -2017- 0066. doi:10.2217/cer -2017 -0066.  
12.  Fetterolf D, Snyder R. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds . 2012;24(10):299- 307.  
13.  Laurent I, Astère M, Wang KR, Cheng Q, Li QF. Efficacy and Time Sensitivity of Amniotic Membrane treatment in Patients with D iabetic Foot Ulcers: A Systematic Review and Meta-
analysis. Diabetes Ther . 2017;8(5):967 -979. doi:10.1007/s13300 -017-0298- 8. 
14.  Branski L, Herndon D, Celis M, Norbury W, Masters O, Jeschke M. Amnion in the treatment of pediatric partial-thickness facial burns.  
15.  Tseng S, Li D, Ma X. Suppression of transforming growth factor- beta isoforms, TGF -beta receptor 
type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by 
amniotic membrane matrix. J Cell Physiol. 1999;179(3) :325- 335.  
16.  Chen E, Tofe A. A literature review of the safety and biocompatibility of amnion tissue. J Implant 
Adv Clin Dent . 2010;2(3):67- 75. 
17.  Mermet I, Pottier N, Sainthillier J, et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen. 2007;15(4):459 -464.  
18.  Zelen C, Serena T, Gould L, et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi- centre comparative study 
examining clinical efficacy and cost. Int Wound J . 2016;13(2):272 -282.  
 Integra LifeSciences  
AMNIOEXCEL® Plus vs Apligraf® vs SOC   Confid ential  Protocol Date 05 Nov 2018  
in the Management of Diabetic Foot Ulcers  
Protocol Version Number 3.0   Page 59 of 59 
19.  Allen L, Powell-Cope G, Mbah A, Bulat T, Njoh E. A Retrospective Review of Adverse Events 
Related to Diabetic Foot UlcersNo Title. Ostomy Wound Manag. 2017;63(6):30 -33. 
20.  Kimmel H, Regler J. An Evidence Based Approach to Treating Diabetic Foot Ulcera tions in a 
Veteran Population. 2011:50 -54. 
21.  Abdo R. Treatment of diabetic foot ulcers with dehydrated amniotic membrane allograft: a prospective case series. J Wound Care . 2016;25(Supplemental 7):S4- 9. 
22.  Lintzeris D, Yarrow K, Johnson L, et al. Use of a Dehydrated Amniotic Membrane Allograft on Lower Extremity Ulcers in Patients with Challenging Wounds: A Retrospective Case Series. Ostomy Wound Manag. 2015;61(10):30 -36. 
23.  Barr SM. Dehydrated Amniotic Membrane Allograft for Treatment of Chronic Leg  Ulcers in 
Patients With Multiple Comorbidities: A Case Series. J Am Coll Clin Wound Spec. 2014;6(3):38- 45. 
doi:10.1016/j.jccw.2016.01.002.  
24.  Rice JB, Desai U, Ristovska L, et al. Economic outcomes among Medicare patients receiving bioengineered cellula r technologies for treatment of diabetic foot ulcers. J Med Econ. 
2015;18(8):586 -595. doi:10.3111/13696998.2015.1031793.  
25.  Snyder RJ, Kirsner RS, Lavery LA, Hanft JR, Sheehan P. Consensus Recommendations on Advancing The Standard Of Care For Treating Ne uropathic Foot Ulcers In Patients With Diabetes. 
Ostomy Wound Manag suppl . 2010;56(Supplemental 4):S1- 24. 
26.  Organogenesis. “How Is It Applied?” Apligraf Website. http://www.apligraf.com/professional/what_is_apligraf/how_is_it_applied/index.html. Publish ed 2010.  
   
 
  END  